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 Plasma proteins have been shown to bind intravenously injected nanoparticles with high affinity and this 
could have potential consequences for drug delivery applications. A subset of plasma proteins, high density 
lipoproteins (HDLs), has been found to form a major component of the biomolecular corona of injected 
nanoparticles and this could possibly lead to nanoparticle therapies being diverted to HDL receptors (SCARBI). 
 I use polystyrene nanoparticles of different surface chemistries (PS, PS-COOH and PS-NH2) and 
determine the affinity of lipoproteins for these nanoparticles. My findings indicate that the strength of binding of 
lipoproteins to nanoparticles in vitro is high enough to effect nanoparticle biodistribution in vivo. My in vitro 
binding studies also reveal that even with competition from other plasma proteins, lipoproteins still bind 
nanoparticles with moderate strength. 
 The ability of lipoproteins to redirect nanoparticles to their receptors upon binding was investigated by 
using mice models lacking SCARBI. Clodronate liposomes are utilized to eliminate the effects of macrophages so 
that I could eliminate background biodistribution. My study demonstrates that HDLs significantly affect nanoparticle 
biodistribution by comparing nanoparticle uptake and plasma lipoprotein cholesterol content in both wild-type and 
SCARBI-/-. Interestingly, nanoparticle uptake is increased in male SCARBI-/- mice following macrophage 
depletion, but the opposite is observed for females. Examination of plasma lipoprotein cholesterol content 
suggests that differences in lipoprotein and lipid metabolism between the genders could account for such 
dissimilarities. 
 To further elucidate the effects of metabolic state on nanoparticle uptake, I intravenously injected C57BL/6, 
KK-Ay and ob/ob mice with nanoparticles called, filomicelles. These mice are given two types of diets: a low-fat diet 
vi 
 
(4 grams/day) and a high-fat diet ad libitum. KK-Ay and ob/ob are known to become obese upon consuming diets 
high in fat. Following obesity status, I observed that localization of filomicelles was reduced in the liver and spleen. 
In another study combining obesity and B-cell lymphoma in a mouse model, I address the potential for obese 
individuals to have a higher risk for advancing B-cell lymphoma. My results from hematology, and 
histopathological examinations of spleen and lymph node tissues indicates that obesity may have the potential to 
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1.1  Background and Significance 
 
 The leading causes of death in the world are due to noncommunicable diseases such as metabolic 
diseases, cardiovascular diseases and cancer. Recent statistical estimates by the World Health Organization show 
that half of the deaths that occurred worldwide in 2016 were attributable to these mentioned noncommunicable 
diseases (NCD) with more than 60% of NCD being related to cardiovascular diseases.1 In the United States, in 
particular, NCD accounted for more than 88% of the 2.8 million deaths that occurred in 2016 with cardiovascular 
diseases (34% of NCD) and cancer (25% of NCD) being the top-killers.1-2  
The rapid rise in these diseases has been linked to the global obesity epidemic.3-4 Current data suggests 
that more than one-third of the world’s population in 2016 was either overweight (Body Mass Index ≥ 25 kg/m2 to 
< 30 kg/m2) or obese (Body Mass Index ≥ 30 kg/m2);5 and if secular trends are to continue, epidemiologist and 
researchers alike have projected that half of the world’s adult population will be overweight or obese by 2030.6-7 In 
the United States, these 2030 projections are pretty steep with over 86% of the adult population being either 
overweight or obese and 51% obese.3, 8  
 Given these dire statistics, there is an overwhelming likelihood that patients that would potentially be 
administered drugs in the clinic will either be overweight or obese. However, the vast majority of studies that are 
carried out to develop and test the effectiveness of these drugs or drug delivery vehicles (e.g. nanoparticles) use 
lean animal models. Therefore, the need for models that explore non-ideal metabolic states is of utmost 
importance. Several elements need to be examined when addressing the effects of non-ideal metabolic states like 
obesity on nanoparticle drug delivery. These may include varying circulating lipoprotein levels, enlarged/fatty livers, 
and associated conditions like, type 2 diabetes or atherosclerosis.  
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 Circulating lipoproteins could limit nanoparticle effectiveness in reaching their desired targets. It has been 
shown in numerous studies that when nanoparticles are exposed to biological fluids (e.g. blood or plasma), 
proteins and other biomolecules bind to their surfaces and form a coating known as the protein or biomolecular 
corona.9-12 A protein or biomolecular corona defines the biological identity of a nanoparticle; therefore, it can exert 
an influence over its clearance kinetics. Lipoproteins have been shown to be components of the biomolecular 
corona in many different nanoparticles with various surface modifications.9-12 Of particular interest are high-density 
lipoproteins (HDLs) that have been found to bind strongly to nanoparticles.10-11  
HDLs could conceivably redirect nanoparticles to HDL receptors (e.g. scavenger receptor class B type I) 
on liver sinusoidal endothelial cells (LSEC) or hepatocytes of the liver,13 endothelial cells of the lung, heart etc.,14 
and thereby diminish the delivery of the therapeutic payload to targets other than tissues or cells that express 
scavenger or lipoprotein receptors. Therefore, pertinent mouse models that test the ability of HDLs to retain their 
functionality after binding nanoparticles would prove useful and insightful given the interaction and function of 
HDLs and its receptors in the body.  
Ultimately, mouse models that combine the effects of metabolic imbalances and cancer would also be of 
great significance since the overall goal is to ultimately evaluate the effects of a patient’s metabolic condition on 
targeted nanoparticle efficacy. 
 
1.2  Factors Impacting Nanoparticle Drug Delivery Efficacy 
 
 Several factors impact the delivery of nanoparticle therapeutics and these may include physicochemical 
properties such as size, shape, surface chemistry, site-specific targeting ligands, etc.15-16 Other factors like the 
aforementioned biomolecular corona and patient metabolic state are also crucial components to nanomedicine and 
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drug delivery efficacy. Due to the intricate nature of biological systems and their effect on drug delivery, it is 
worthwhile to address these factors as they would provide for a more streamlined approach in the application of 
targeted drug delivery systems. 
 
1.2.1  Biomolecular Corona 
 
 Nanoparticles injected into the bloodstream are exposed to thousands of blood proteins and other 
biomolecules (e.g. nucleic acids, sugars) which compete for the nanoparticle surface.12, 17-18 The process of 
biomolecular corona formation occurs whereby the kinetics of binding initial favor the most abundant proteins in 
the bloodstream but over a relatively short period of time (seconds to minutes) these are replaced by proteins of 
higher affinity.18-19 As the nanoparticle travels from one biological environment to another, it embodies this 
biomolecular corona “fingerprint” which can determine further associations and interchanges in its new 
environment.18, 20 Clearly, this biomolecular “fingerprint” is important in drug delivery efficacy because it can dictate 
the recognition of nanoparticle-biomolecular corona complexes by the immune system or cell-surface receptors. 
Recognition of these nanoparticles is facilitated by proteins that may or may not undergo conformational changes 
and have exposed epitopes in the biomolecular corona.21  
It is important to note, however, that proteins in the biomolecular corona can function as opsonins and 
dysopsonins.22 Dysopsonin adsorption reduces the recognition of nanoparticles by the immune system, thus, 
extending its circulation time in the body.22 As an example, apolipoproteins and albumin have been shown to bind 
nanoparticles and decrease the adsorption of opsonins such as immunoglobulin G and complement factors, 
hence inhibiting complement activation.23-24 Although complement activation can lead to the rapid clearance of 
nanoparticles in the body, it is not the only mechanism by which to predict nanoparticle clearance. A recent study 
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reported by Bertrand and coworkers25 have showed that poly(ethylene glycol)-b-poly(lactic co glycolic acid) (PEG-
PLGA) nanoparticles with low steric hindrance and absorbed apolipoprotein E (ApoE) protect the nanoparticles 
against rapid opsonization and increases blood circulation time in experiments that implemented C57BL/6 and 
ApoE-/- mice models. More importantly, they observed similar levels of complement protein C3 and other 
complement components on PEG-PLGA nanoparticles that displayed rapid and slow clearances in experiments 
that implemented C57BL/6 and complement protein C3-/- mice models. Ultimately, they demonstrated that low-
density lipoprotein receptors could also be essential to the rapid clearance of nanoparticles because of the 
presence of ApoE in the biomolecular corona. 
Evidently, the composition of the biomolecular corona is important to nanoparticle drug delivery but the 
question that requires more probing is which proteins or biomolecules in the biomolecular corona are “most 
relevant” to evaluating therapeutic effectiveness. The simple answer is, it depends. There are several complex 
elements that need to be taken into consideration. For example, the fact that every human has a unique blood 
profile that also changes with disease type coupled with different routes for nanoparticle drug administration can 
affect which proteins or biomolecules are considered “most relevant”.21, 26-27 In addition, the composition of the 
biomolecular corona is unique to each nanomaterial type, and dissimilar physicochemical properties also influence 
the biomolecular corona composition thus adding another facet of complexity to finding a one-size-fits-all solution 
to nanoparticle drug delivery.15 Therefore, one possible approach would be to have a repository where you can 
resolve the biomolecular corona of each nanoparticle type tailored to specific disease conditions. Various models 
could also be built to predict nanoparticle biological outcome after identities of potential candidates from the 
biomolecular corona are established. This proposal is plausible because we can model binding affinity constants 
for nanoparticle-protein interactions and there have already been quantitative and computational efforts to advance 
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our understanding of the biomolecular corona as it relates to predicting nanoparticle-cell association,28-31 
biodistribution,32-33 and toxicity28-29, 32.  
 Although computational developments are far from being fully realized, we can nonetheless peruse 
research studies in literature to look at major proteins of the biomolecular corona that form on different 
nanomaterials. Walkey and Chan did an extensive review on plasma proteins that bound to 63 nanomaterials by 
compiling data from 26 independent research studies.34 In their review, they discovered a subset of 125 unique 
plasma proteins that bound to at least one of the 63 nanomaterials. Of these 125 plasma proteins, 21 were found 
to constitute greater than 10% of the total absorbed biomolecular corona mass and were termed “high abundance” 
proteins. 15 of the 21 high abundance proteins were found to be associated with lipoproteins, particularly HDLs 
(Table 1.1). These associations were made by cross-matching to a compendium of HDL associated proteins by 
Davidson and coworkers (Figure 1.1).35-36 It should also be noted that approximately two-thirds of the 125 plasma 
proteins were listed in the compendium of either the HDL or LDL proteome watch list. In general, the 125 plasma 
proteins discovered on the 63 nanomaterials are involved in physiological roles related to lipid metabolism and 
transport, complement activation, immune response, inflammation, hemostasis, and metal binding or ion 
transport.35, 37  
With knowledge of plasma proteins or biomolecules that form the core of the biomolecular corona, 
scientists can then exploit such information to predict physiological responses and enhance therapeutic potential. 
Obviously, care should be taken as with any model to determine its scope and applicability since not all systems 
are translatable. A simple example is that not all in vitro systems translate in vivo; but studies that combine in vitro, 




Table 1.1  High absorbance proteins (>10% in biomolecular corona) associated with HDLs and LDLs34-36 
 
Protein HDL* LDL* 
Apolipoprotein A-I 1 1 
Apolipoprotein A-IV 1 1 
Apolipoprotein B-100 0 1 
Apolipoprotein C-II 1 1 
Apolipoprotein C-III 1 1 
Apolipoprotein E 1 1 
Clusterin 1 1 
Complement C3 1 0 
Fibrinogen 1 1 
Haptoglobin 1 0 
Hemoglobin 1 0 
Histidine-rich glycoprotein 1 0 
Ig gamma chain 1 0 
Inter alpha trypsin inhibitor H1 1 0 
Paraoxonase-1 1 0 
Serum albumin 1 1 





Figure 1.1  Venn diagram showing the distribution of biomolecular corona as related to the lipoproteome34-36 
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 1.2.2  Nanoparticle Properties: Effect of Size and Shape 
 
The size and shape of nanoparticles play important roles in margination dynamics, opsonization, cellular 
uptake and biodistribution. Overcoming barriers to nanoparticle drug delivery can be made possible by designing 
nanoparticles of different sizes and shapes to accumulate in desired tissues or cells of interest. Recognizing the 
roles and limitations of these factors (size and shape) in assessing nanoparticle design parameters is important to 
the field of drug delivery. 
 
1.2.2.1  Effect of Particle Size and Shape on Margination  
 
The tendency for nanoparticles to laterally drift towards endothelial walls is beneficial for nanoparticle-cell 
associations and in theory could improve the likelihood of site-specific active targeting (e.g. cancerous tumors). 
Conventionally speaking, this phenomenon is usually assigned to free-flowing leukocytes and platelets that exit the 
central blood flow and localize to a region near vessel walls known as the red blood cell-free layer; therefore, it is 
only befitting that nanoparticles be fine-tuned with similar geometries of these blood components to achieve the 
intended benefits of marginating to this red blood cell-free layer (Figure 1.2). Researchers have studied this 
margination propensity by implementing mathematical models, and their findings demonstrated that particles 
possessing a typical spherical geometry are less likely to marginate to vessel walls than nonspherical particles.38-41 
In addition to mathematical models, studies that assessed margination dynamics in more physiological conditions 
have also shown that particle size and shape are important to marginating to vessel walls.42-46  
Lee and coworkers investigated the importance of particle size on margination dynamics by employing 
intravital microscopy to monitor the flow of 200 nm and 1000 nm PEGylated fluorescent polystyrene spheres in 





Figure 1.2  Nanoparticle margination to red blood cell-free layer 
 
 
effectively pushed laterally to the vessel walls by red blood cells. Simulations of transport within whole blood were 
run by the group and also showed this size-dependent behavior with larger particles (500 nm and 1000 nm) 
having better margination dynamics than smaller ones (10 nm, 50 nm and 100 nm). These results would imply 
that sub-micron to micron-sized spherical particles are more effectively pushed laterally to vessel walls and may be 
favored for vascular targeting than traditional nanospheres with sizes ranging from 10 nm to 100 nm. Charoenphol 
and coworkers also examined the effect of particle size on margination dynamics and their results provide support 
to the fact that larger-sized spherical particles marginate to vessels walls more effectively than their smaller-sized 
counterparts.43 In their in vivo study, they used ApoE-/- mice aortas to investigate the adhesion of 0.5 µm and 2 
µm vascular-targeted (sialyl lewis A and anti-VCAM-1) fluorescent polystyrene spheres. Results from the study 
indicated that 2 µm particle adhesion densities were 2.5 – 3.5-fold higher in all major segments of mice aorta than 
the 0.5 µm spheres, pointing to better margination efficiency for the 2 µm spheres.  
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It should be noted that theoretical models have predicted that within a capillary flow, adhesion strength 
reduces as spherical particle diameter increases (d > ~560 nm) because of higher dislodging forces experienced 
by larger spherical particles,47 so it may be unlikely that adhesion strength would be particularly relevant in the 
Charoenphol study. Also, the surface density of ligand/antibody was the same for both spherical particles. In any 
case, regardless of the site-specific targeting moiety used on a nanoparticle, if it does not have substantial 
margination efficiency it would not be able to reach the vicinity of vessel walls to make contact with potential 
receptors. In the Charoenphol study, gravity would more than likely play a role in the margination of the larger 
spherical particles to the vessel walls since gravitational forces become more significant as particle size increases 
(d > 500 nm).40, 48 Another point worth mentioning is that a mere increase in size does not always necessitate 
better margination efficiency because other factors like the relative particle density, Brownian diffusion or van der 
Waals interaction forces can affect margination to vessel walls.40, 44, 49  
For instance, an increase in size of the neutrally-buoyant nanoparticles (10 nm, 50 nm and 100 nm) from 
the above-discussed simulation work of Lee and coworkers did not show any significant improvement in 
margination efficiency and all nanoparticles ultimately resided in the vessel core. In a study by Toy and 
coworkers,44 increasing the size of neutrally-buoyant liposomes (65 nm, 100 nm and 130 nm) caused a decrease 
in margination to vessel walls in experiments that utilized a fibronectin-coated polydimethylsiloxane microchannel 
for monitoring margination dynamics. Given that the contribution of gravity was neglected for these liposomes, the 
decrease in margination was reasoned to be attributed to larger momentum values exceeding the diffusion 
component of the liposomes towards the channel walls. Decuzzi and coworkers49 used theoretical models to study 
the margination of particles to blood vessel walls and they demonstrated that a critical radius value exist by which 
time to margination would increase up to this value before decreasing past this critical point (Figure 1.3). The 
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model showed that the critical radius was dependent on the relative density of the particle to blood to the effect that 
when relative density decreased the critical radius increased. Furthermore, as the relative density decreased van 
der Waals forces became more dominant for nanoscale particles. In other words, the critical radius would be 
higher for particles with densities closer to that of blood with buoyancy being less of an influence as particle size 
decreased to the nanoscale. Therefore, it could be possible that the sizes of the liposomes studied in Toy and 
coworkers’ study was well away from its critical radius for the experimental setup. It should be pointed out, 
however, that both the Toy and Decuzzi study were undertaken with the exclusion of blood components which are 
crucial to margination dynamics since particle collisions with red blood cells could also affect lateral displacement 





Figure 1.3  Time to margination as a function of particle radius for Δρ = 103 and 104 relative density values. 
Adapted from ref.49  
 
 
An in vivo study by D’Apolitio and coworkers45 was conducted to determine the effect of particle shape on 
the margination of fluorescently labeled poly(lactic-co-glycolic acid) (PLGA) microparticles in skin vessels of 
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transgenic Tie2-green fluorescent protein (GFP expressed on vascular endothelium) mice. They employed 
intravital confocal microscopy to visualize the flow dynamics of PLGA spheres (1 µm), discs (d: 1 µm x h: 400 nm) 
and rods (d: 400 nm x h: 1.8 µm) of equal volume. Their findings indicated that the rods had the lowest 
margination propensity while discoidal and spherical microparticles had similar margination propensity. In another 
work by Thompson and coworkers,46 the margination propensity of spherical and rod-shaped particles of different 
equivalent spherical diameters (ESDs) and aspect ratios (ARs) was studied under blood flow in a parallel plate flow 
chamber lined with human umbilical vein endothelial cells. Results from the experiments showed that rod-shaped 
particles with high ARs ≥ 9 (and ESDs ≥ 1 µm) had better margination propensity – as measured by particle wall 
binding – than equivalent spheres particularly at high shear rates and disturbed flow profiles. Nanorods (500 nm 
ESD), however, did not show any improvement in particle wall binding when compared with equivalent spheres, 
even at high ARs.  
It should be mentioned that confocal imaging from experiments run under laminar blood flow (30% 
hematocrit) and at the highest wall shear rate revealed that there was no difference in localization of rod-shaped 
particles (AR 4 and 9) or equivalent spheres to the red blood cell-free layer for particles with an ESD of 2 µm. 
However, there was decreased localization for rod-shaped particles for the highest AR studied (AR = 11) when 
compared with equivalent spheres at an ESD of 1 µm. These experiments suggest that particle adhesion improved 
the results observed for rod-shaped particles. This brings up an important point of separating particle margination 
from particle adhesion since the latter is influenced by other factors such as particle ligand/antibody distribution, 
receptor density, binding strength etc. To better understand relationships between specific nanoparticle properties 
and margination in blood flow, studies need to clearly distinguish between particle margination and particle 
adhesion to prevent confounding by the latter.  
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1.2.2.2  Effect of Particle Size and Shape on Cellular Uptake 
 
 Following nanoparticle margination and site-specific adhesion, nanoparticles have to interact with the 
extracellular matrix or external membranes of target cells and then traverse this plasma membrane to deliver their 
therapeutic payload through endocytosis. Endocytosis can be classified according to different mechanisms as 
determine by cell type, nanoparticle-biomolecular corona or other targeting moieties.21, 50 Broadly speaking, the 
process would involve the wrapping of nanoparticles by the cell membrane for membrane budding that is 
subsequently pinched off to form an endocytic vesicle, followed by sorting and trafficking of the endosomal 
contents to other specialized intracellular compartments.50 Since nanoparticle cellular internalization and 
compartmentalization are essential in governing the successful delivery of its cargo, it is important to understand 
how nanoparticle properties affect such processes.  
 Jiang and coworkers studied the cellular internalization of Herceptin-coated gold and silver nanospheres 
(2 – 100 nm) in human breast cancer SK-BR-3 cells overexpressing ErbB2 receptor.51 Their study showed that 
size played an important role in cellular uptake with the 40 nm and 50 nm sized nanospheres having the most 
significant uptake. The increased internalization observed for these nanoparticle sizes was attributed to the greater 
affinity for the receptor binding sites. As size increased, so did the affinity of the nanoparticles for the receptor 
binding sites. However, the decrease in internalization observed for the larger-sized nanoparticles was ascribed to 
limited membrane wrapping. In another study, Lu and coworkers investigated the cellular internalization of 
mesoporous silica nanospheres (30 – 280 nm) in HeLa cells.52 Results of the study indicated that 50 nm-sized 
particles were highly internalized by HeLa cells with cellular uptake in the following order 50 > 30 > 110 > 280 > 
170 nm. Other researchers have also reported similar results with nanoparticle sizes around 50 nm being optimal 
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for cellular uptake;53-59 however, this overall trend could possibly be a characteristic of non-phagocytic cells (Table 
1.2). It is unclear if phagocytic cells display similar size-dependent uptake of nanospheres (Table 1.2).55, 60-65 
 Besides nanoparticle size, the nanoparticle shape can also have a significant impact on its cellular 
internalization. Barua and coworkers found that trastuzumab-coated polystyrene nanorods provided better cellular 
uptake than nanodiscs and nanospheres in BT-474 and SK-BR-3 breast cancer cell lines, with nanospheres 
exhibiting the lowest uptake.66 The increased uptake of nanorods over nanodiscs and nanospheres was ascribed 
to higher multivalent binding of trastuzumab to cell receptors as a result of increased contact area with the cell 
surface. Uptake of uncoated polystyrene nanorods and nanodiscs were less than nanospheres in tests with BT-
474 cells pointing perhaps to enhanced coating and presentation of trastuzumab-coated nonspherical particles. 
Xinglu and coworkers probed the cellular uptake of mesoporous silica nanoparticles (MSNPs) of different ARs (AR 
= 1, AR = 2 and AR = 4) in A375 human melanoma cells and found that nanoparticles with larger ARs experienced 
higher and rapid internalization than nanoparticles with smaller ARs.67 In contrast to these studies, Chithrani and 
coworkers have showed that rod-shaped gold nanoparticles exhibited lower cellular uptake in HeLa cells when 
compared with spherical gold nanoparticles (AR = 1 > AR = 3 > AR = 5).68 They reasoned that the lower uptake of 
nanorods was possibly due to the presence of residual surfactant because the nanorods were fabricated with cetyl 
trimethylammonium bromide that may have not been completely removed from the surface of the gold nanorods. 
Another reason posited was that membrane wrapping could have taken longer for nanorods since in addition to 
the AR, the absolute size and/or volume of the particle could have affected cellular internalization kinetics.69  
In terms of shape-dependent cellular uptake by phagocytic cells, Champion and Mitragotri have 
suggested that macrophages are able to use the local curvature of a particle at the point of initial contact to 
determine whether or not to initiate phagocytosis, or merely spread on the particle which they called “frustrated”  
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Table 1.2  Summary of size-dependent cellular uptake 
 
Nanoparticle(a) Size range (nm) Optimal size (nm) Cell line Reference 
Gold 2 – 90 40, 50 SK-BR-3 [51] 
Silver 5 – 90 40, 50 SK-BR-3 [51] 
MSN 30 – 280 50 HeLa [52] 
PS 20 – 100 40 1321N1, A549 [53] 
Gold 45 – 110 45 HeLa, CL1-0 [54] 
Gold 16 – 58 40(b) Raw 264.7, HepG2 [55] 
Gold 10 – 50 50 NRK [56] 
Gold 25 – 50 50 PANC1, Jurkat [57] 
LDH 50 – 350 50 MNNG/HOS [58] 




PSCOOH 20 – 200 20 J774.A1 [60] 
PVP-IO 8 – 65 37 Raw 264.7 [61] 
PSCOOH 40 – 2000 40 






62 – 394 394 HMDM [63] 
Silica-coated IO 30 – 120 None HMDM, MDDC [64] 
Dextran-coated 
SPIO 
20, 50  None HMDM [64] 
Silver(c) 20 – 75 20 THP-1 [65] 
Silver(d) 20 – 75 50, 75 THP-1 [65] 
(a) All spherical particles. (b) Positively charged gold nanoparticles displayed no size-dependent uptake. (c) Without fetal calf serum treatment. (d) With fetal calf serum treatment. MSN – 
mesoporous silica nanoparticles; PS – polystyrene; LDH – layered double hydroxide; PSCOOH – carboxylate-functionalized polystyrene; PVP-IO – Polyvinylpyrrolidone-coated iron oxide; 













phagocytosis.70 They studied the phagocytosis of six different shapes (prolate ellipsoid, oblate ellipsoid, elliptical 
disc, rectangular disc, UFO and spheres) in NR8383 alveolar rat macrophages and determined the success of  
phagocytosis by two dimensionless parameters, Ω and V*, where Ω was related to the shape of the particle and 
the point of attachment on the macrophage while V* was defined as the ratio of the particle volume to macrophage 
volume. The authors used a phase diagram (Figure 1.4) to illustrate the regions of successful internalization (Ω ≤ 
45°, V* ≤ 1), unsuccessful internalization (Ω ≤ 45°, V* ≥ 1) and spreading (Ω > 45°). Their results suggested that 
shape played a major role in the induction of the phagocytosis process and size mainly affected total particle 
engulfment when the volume of the particle was greater than that of the macrophages. 
Padmore and coworkers reported frustrated phagocytosis after the exposure of short and long glass fibers 
to murine alveolar macrophages.71 They identified critical lengths (12 µm and 27 µm, d ~0.8 µm) by which 
frustrated phagocytosis occurred by fitting dose-response curves of stimulated cytokines (IL-1α and TNF-α) to 
short and long glass fiber populations. Differences in critical lengths stemmed from the potency and weighting of 
short and long glass fibers towards cytokine response. Concerning the overall uptake, their investigations showed 
that macrophage internalization events were less for longer fibers when compared with shorter fibers. 
 Analyses by other researchers also indicated that using higher AR or elongated particles increased the 
possibility of frustrated phagocytosis and/or immune evasion.72-75 However, for successfully phagocytosed 
nonspherical particles, high AR has also been associated with increased uptake, but this alone does not determine 
the total amount of particles internalized as discussed earlier for non-phagocytic cells. For example, Arnida and 
coworkers76 found that PEGylated gold nanorods were less readily internalized than PEGylated nanospheres in 
RAW 264.7 macrophages, but in another work by Bartneck and coworkers77 they obtained contrasting results for 





Figure 1.4  (A) The relationship between internalization velocity and Ω for different nanoparticle shapes. 














human blood macrophages was comparable for amine- and carboxyl-terminated PEGylated gold nanorods and 
nanospheres, thus particle shape did not influence the uptake of these nanoparticles.  
In summary, literature suggests that nanoparticle shape and size can be exploited to increase or decrease 
the cellular uptake of nanoparticles. Although general conclusions can be made regarding the size and shape of 
nanoparticles, a better understanding of the interplay of nanoparticle characteristics, cell type and mechanism of 
internalization is needed for the rational design of drug delivery vehicles. In addition, in vitro research that closely 
resembles physiological conditions should be considered in future developments. 
 
1.2.2.3  Effect of Particle Size and Shape on Biodistribution 
 
 Nanoparticles injected intravenously have to pass through the hurdles of the body’s immune system, that 
includes the mononuclear phagocyte system, to eventually reach their intended destination. Major organs of the 
body that are associated with the mononuclear phagocyte system, such as the liver and spleen, have filters that 
could preclude nanoparticle delivery to desired regions. The liver embodies discontinuous endothelia with vascular 
fenestrations that have sizes that range from 50 – 180 nm,78 while the spleen has interendothelial cell slits that 
range in size from 200 – 500 nm.79 Kidneys have a glomerular filtration system that utilize fenestrated blood 
capillaries and podocyte slit diaphragms to filter particles that are < 5 nm,80 and the lungs are known to have 
micrometer-sized particles readily accumulate within its capillaries.81 Nanoparticles generally experience rapid 
clearance from the aforementioned organs based on the cut-off pore size of the organ’s filtration system, unless 
the particles’ material structure and fluid dynamics are such that they allow extension and alignment with the flow 
of blood or streamlines around macrophages, as is the case with flexible filamentous polymer micelle assemblies 
(also known as filomicelles).72 
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Discher and coworkers showed that longer filomicelles composed of a hydrophilic poly-ethylene glycol 
(PEG) corona and either a hydrophobic core of biodegradable polycaprolactone (PCL) or inert poly-ethyl-ethylene 
were able to persist in circulation for longer periods of time when compared with shorter filomicelles (L0, 18 µm ≥ 
8 µm > 4 µm > 2 µm; d0, 22 nm to 60 nm) and spherical vesicles.72 Filomicelles of greater contour lengths were 
able to stay in circulation for up to a week while their spherical counterparts were cleared within 2 days, and this 
difference could have been due to the breakdown of the longer filomicelles into smaller fragments coupled with 
inefficient uptake of the particles by phagocytic cells. Biodistribution of the particles in Sprague-Dawley rats 
following 4 days after intravenous injection displayed the highest distribution of the PCL filomicelles (L0 = 4 µm or 
8 µm) in the liver and spleen, with distributions to the lungs and kidneys to a lesser extent.  
In another study by Discher and coworkers,82 they compared the ability of paclitaxel loaded filomicelles 
and spherical micelles to shrink xenografted tumors (human lung carcinoma cell line, A549) in Ncr nude mice. 
Their study demonstrated that filomicelles were able to increase the maximum tolerated dose of paclitaxel relative 
to spherical micelles, and the paclitaxel loaded filomicelles had the most inhibitory effect on tumor growth possibly 
due to the higher dose and the ability of filomicelles to reptate into the leaky tumor vasculature. Besides, following 
24 hours of injection with filomicelles and spherical micelles of the same paclitaxel dose (8 mg/kg), the filomicelles 
exhibited greater tumor/organ selectivity when compared with spherical micelles. The effect of this selectivity could 
be observed in the percent change of tumor/organ apoptosis from utilizing spherical micelles and filomicelles 
following 22 days of multiple 8 mg/kg injections: tumor/liver, +29%; tumor/kidney, +31%; tumor/spleen, +38%; 
tumor/heart, +60% and tumor/lung, +61%.  
A recent study reported by Kaga and coworkers83 to investigate the influence of size and shape on the 
biodistribution of poly(glycidyl methacrylate)-b-poly(oligo- (ethylene glycol) methyl ether methacrylate)-b-
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polystyrene (PGMA-b-POEGMA-b-PS) block copolymer nanoparticles demonstrated higher degrees of 
accumulation in the liver and spleen as the overall nanoparticle size increased. The nanoparticle form and 
dimensions are as follows: spherical micelles, d: 21 nm and 33 nm; rodlike micelles, d: 37 nm, contour length: 
350 nm – 450 nm; wormlike micelles, d: 45 nm, contour length: 1 – 2 µm. Biodistribution of nanoparticles in the 
HT1080 tumor-bearing athymic nude mice also showed that most of the nanoparticles were cleared from the 
blood within 2 days, and nanoparticle tumor accumulation decreased as overall nanoparticle size increased. 
Additionally, wormlike micelles had the most accumulation in the lungs while the distribution of other nanoparticles 
decreased as overall size increased. The smaller spherical micelles (21 nm) also had the highest biodistribution in 
the kidneys, pancreas and heart.  
Müllner and coworkers84 found that increasing the rigidity and aspect ratio of cylindrical polymer brushes 
(PEGMA-co-GMA, PCL-b-(PEGMA-co-GMA)) produced greater plasma clearance following intravenous injection 
in rats. This greater plasma clearance for higher AR cylindrical polymer brushes is in contrast to the works by 
Discher and coworkers where higher ARs for filomicelles resulted in greater circulation times. Such disparity could 
stem from the stability of the backbone of the cylindrical polymer brushes employed by Müllner and coworkers as 
opposed to the self-assembled filomicelles from the works of the Discher and coworkers that experienced 
fragmentation following intravenous injection, thus supporting their prolonged residence in circulation. Apart from 
an increase in clearance, the higher AR cylindrical polymer brushes also brought about greater deposition in 
mononuclear phagocyte system (MPS) organs with the most notable uptake occurring in the liver and spleen. 
Decuzzi and coworkers examined the influence of size (700 nm – 3 µm) and shape (discoidal, spherical, 
hemispherical and cylindrical; v ≈0.6 µm3) on the biodistribution of silica or silicon nanoparticles in xenografted 
MDA-MB-231 tumor-bearing nu/nu nude mice.81 Their investigations showed that majority of the spherical 
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particles accumulated in the liver, lung and spleen. At a higher dose, the smallest spherical particle, 700 nm, had 
the most accumulation in the liver and the larger spherical particles, 2.5 µm and 3.0 µm, had significant 
accumulation in the lungs as expected. Tumor accumulation decreased as spherical particle size increased. 
Discoidal particles were shown to accumulate significantly more in the lungs and heart when compared with 
hemispherical, cylindrical and spherical particles. On the other hand, cylindrical particles accumulated significantly 
more in the liver when compared with other non-spherical and spherical particles. There was higher accumulation 
of discoidal and hemispherical particles in the spleen when compared with cylindrical and spherical particles. No 
significant differences in shape effects were found for particle accumulation in the brain, kidneys and tumor. It is 
possible that the higher accumulations observed for discoidal particles in most organs were as a result of better 
margination propensity; however, lower accumulations for the liver was attributed to the inability of liver 
macrophages to engulf the particles because of their elongated shapes. 
 Black and coworkers studied the biodistribution of 50 nm PEGylated radioactive gold particles of different 
shapes (nanodiscs, nanospheres, nanorods and nanocages) in EMT6 tumor-bearing Balb/c mice.85 Twenty-four 
hours post intravenous injection, the nanostructures were mainly distributed to the liver and spleen. Nanodiscs 
and nanocages displayed greater accumulation in the lungs and spleen when compared with other nanoparticle 
shapes, while nanospheres and nanocages had higher accumulations in the heart than the other nanostructures. 
Tumor deposition was highest for the nanospheres and this may have been due to increased retention of 
nanospheres in blood circulation and a lower clearance by the liver and spleen. Nanorods exhibited the lowest 
tumor deposition (nanospheres > nanocages > nanodiscs > nanorods) and this was attributed to the low coverage 
density of PEG on the particle surface. 
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 Overall, these studies indicate that PEGylation increases the circulation time of nanoparticles in the body 
and that size and shape play important roles in biodistribution. In order to effectively target specific organs, particle 
size and shape need to be tailored to maximize delivery. In the case of tumors, smaller nanoparticles would be 
ideal for enhanced permeability but changes to the tumor microenvironment may also change the effective size for 
tumor uptake. Therefore, in order to exploit the nanomaterial’s properties, careful consideration of the nature of the 
disease and desired target should help guide nanoparticle design. 
 
1.3  Conclusions 
 
 With the ultimate goal of designing drug delivery systems to deliver their cargos to specific targets, the 
efforts that have been made to accomplish this prove that recognition by the immune system or opsonization are 
still major obstacles to successful developments. Changes in the metabolic state of an individual have therefore 
become an essential component to consider when evaluating therapeutic options to be administered because this 
could affect drug delivery.  
Nanoparticle technologies for drug delivery are growing and the rational design of these technologies to 
overcome the above barriers to effective treatment require that we understand the relationship between 
nanoparticle properties, biomolecules in different biological environments, the biomolecular corona, and the 
complexities surrounding the disease. The use of particle fabrication methods to form and modify nanoparticle 
shapes are becoming increasingly relevant to achieve this particular aim. Not only are particle sizes and shapes 
important parameters that determine margination efficiency to vessel walls, they are also crucial properties that can 
be exploited to evade recognition by the immune system. The AR of nanoparticles can be adjusted to “frustrate” 
phagocytosis and decrease cellular internalization. Generally, nanoparticles of higher AR can be used to this effect 
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and PEGylation of nanoparticles also offer steric hindrance against opsonization and tend to promote increased 
blood residence time. Sequestration of nanoparticles by MPS organs can thus be limited for prolonged periods, 
sometimes up to days, thereby increasing the probability of nanoparticles arriving at their destination. 
Although nanoparticle fabrication techniques exist that are geared to evade the immune system, there is 
still more work to be done to deepen our understanding of how the biomolecular corona formed on nanoparticle 
surfaces affects such opsonization and subsequent biodistribution. Numerous nanomaterials are available, and the 
biomolecular corona composition varies based on the properties of these nanomaterials. However, lipoproteins 
and the like are major constituents of many nanoparticle biomolecular coronas and should be investigated in 
further detail. This would be particularly important since lipid metabolism and lipoprotein receptors may be major 
aspects affecting nanoparticle drug delivery efficacy. Consequently, it is of paramount importance that we establish 
key elements governing the interconnectedness between metabolic conditions, nanoparticle corona formation and 







1. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2016; World 
Health Organization: Geneva, 2018. 
2. World health statistics 2018: monitoring health for the SDGs, sustainable development goals; World 
Health Organization: Geneva, 2018. Licence: CC BY-NC-SA 3.0 IGO. 
3. Hruby, A.; Hu, F. B., The Epidemiology of Obesity: A Big Picture. Pharmacoeconomics 2015, 33 (7), 673-
689. 
4. Romieu, I.; Dossus, L.; Barquera, S.; Blottière, H. M.; Franks, P. W.; Gunter, M.; Hwalla, N.; Hursting, S. 
D.; Leitzmann, M.; Margetts, B.; Nishida, C.; Potischman, N.; Seidell, J.; Stepien, M.; Wang, Y.; Westerterp, K.; 
Winichagoon, P.; Wiseman, M.; Willett, W. C., Energy balance and obesity: what are the main drivers? Cancer 
Causes & Control 2017, 28 (3), 247-258. 
5. Global Health Observatory: Overweight and Obesity, 1975-2016; World Health Organization: Geneva, 
2018. 
6. Kelly, T.; Yang, W.; Chen, C.-S.; Reynolds, K.; He, J., Global burden of obesity in 2005 and projections to 
2030. International Journal of Obesity 2008, 32, 1431-1437. 
7. Finkelstein, E. A.; Khavjou, O. A.; Thompson, H.; Trogdon, J. G.; Pan, L.; Sherry, B.; Dietz, W., Obesity 
and severe obesity forecasts through 2030. American Journal of Preventive Medicine 2012, 42 (6), 563-570. 
8. Wang, Y.; Beydoun, M. A.; Liang, L.; Caballero, B.; Kumanyika, S. K., Will all Americans become 
overweight or obese? estimating the progression and cost of the US obesity epidemic. Obesity 2008, 16 (10), 
2323-2330. 
9. Yan, X.; Kuipers, F.; Havekes, L. M.; Havinga, R.; Dontje, B.; Poelstra, K.; Scherphof, G. L.; Kamps, J. A., 
The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. Biochemical 
and Biophysical Research Communications 2005, 328 (1), 57-62. 
10. Cukalevski, R.; Lundqvist, M.; Oslakovic, C.; Dahlbäck, B.; Linse, S.; Cedervall, T., Structural Changes in 
Apolipoproteins Bound to Nanoparticles. Langmuir 2011, 27 (23), 14360-14369. 
11. Dell'Orco, D.; Lundqvist, M.; Oslakovic, C.; Cedervall, T.; Linse, S., Modeling the Time Evolution of the 
Nanoparticle-Protein Corona in a Body Fluid. PLoS One 2010, 5 (6), e10949. 
12. Hellstrand, E.; Lynch, I.; Andersson, A.; Drakenberg, T.; Dahlbäck, B.; Dawson, K. A.; Linse, S.; Cedervall, 
T., Complete high‐density lipoproteins in nanoparticle corona. Federation of European Biochemical Societies 
2009, 276, 3372-3381. 
13. Ganesan, L. P.; Mates, J. M.; Cheplowitz, A. M.; Avila, C. L.; Zimmerer, J. M.; Yao, Z.; Maiseyeu, A.; 
Rajaram, M. V. S.; Robinson, J. M.; Anderson, C. L., Scavenger receptor B1, the HDL receptor, is expressed 
abundantly in liver sinusoidal endothelial cells. Scientific Reports 2016, 6, 20646. 
14. Vaisman, B. L.; Demosky, S. J.; Stonik, J. A.; Ghias, M.; Knapper, C. L.; Sampson, M. L.; Dai, C.; Levine, 
S. J.; Remaley, A. T., Endothelial expression of human ABCA1 in mice increases plasma HDL cholesterol and 
reduces diet-induced atherosclerosis. Journal of Lipid Research 2012, 53 (1), 158-167. 
15. Nel, A. E.; Mädler, L.; Velegol, D.; Xia, T.; Hoek, E. M. V.; Somasundaran, P.; Klaessig, F.; Castranova, V.; 




16. Alexis, F.; Pridgen, E.; Molnar, L. K.; Farokhzad, O. C., Factors Affecting the Clearance and Biodistribution 
of Polymeric Nanoparticles. Molecular Pharmaceutics 2008, 5 (4), 505-515. 
17. Nanjappa, V.; Thomas, J. K.; Marimuthu, A.; Muthusamy, B.; Radhakrishnan, A.; Sharma, R.; Khan, A. A.; 
Balakrishnan, L.; Sahasrabuddhe, N. A.; Kumar, S.; Jhaveri, B. N.; Sheth, K. V.; Khatana, R. K.; Shaw, P. G.; 
Srikanth, S. M.; Mathur, P. P.; Shankar, S.; Nagaraja, D.; Christopher, R.; Mathivanan, S.; Raju, R.; Sirdeshmukh, 
R.; Chatterjee, A.; Simpson, R. J.; Harsha H. C.; Pandey, A.; Keshava Prasad T. S., Plasma Proteome Database as a 
resource for proteomics research: 2014 update. Nucleic Acids Research 2014, 42 (Database issue), D959-D965. 
18. Ke, P. C.; Lin, S.; Parak, W. J.; Davis, T. P.; Caruso, F., A Decade of the Protein Corona. ACS Nano 2017, 
11, 11773-11776. 
19. Tenzer, S.; Docter, D.; Kuharev, J.; Musyanovych, A.; Fetz, V.; Hecht, R.; Schlenk, F.; Fischer, D.; Kiouptsi, 
K.; Reinhardt, C.; Landfester, K.; Schild, H.; Maskos, M.; Knauer, S. K.; Stauber, R. H., Rapid formation of plasma 
protein corona critically affects nanoparticle pathophysiology. Nature Nanotechnology 2013, 8, 772-781. 
20. Lundqvist, M.; Stigler, J.; Cedervall, T.; Berggård, T.; Flanagan, M. B.; Lynch, I.; Elia, G.; Dawson, K., The 
Evolution of the Protein Corona around Nanoparticles: A Test Study. ACS Nano 2011, 5 (9), 7503-7509. 
21. Monopoli, M. P.; Åberg, C.; Salvati, A.; Dawson, K. A., Biomolecular coronas provide the biological 
identity of nanosized materials. Nature Nanotechnology 2012, 7, 779-786. 
22. Nguyen, V. H.; Lee, B.-J., Protein corona: a new approach for nanomedicine design. International Journal 
of Nanomedicine 2017, 12, 3137-3151. 
23. Peng, Q.; Zhang, S.; Yang, Q.; Zhang, T.; Wei, X. Q.; Jiang, L.; Zhang, C. L.; Chen, Q. M.; Zhang, Z. R.; 
Lin, Y. F., Preformed albumin corona, a protective coating for nanoparticles based drug delivery system. 
Biomaterials 2013, 34 (33), 8521-8530. 
24. Amici, A.; Caracciolo, G.; Digiacomo, L.; Gambini, V.; Marchini, C.; Tilio, M.; Capriotti, A. L.; 
Colapicchioni, V.; Matassa, R.; Familiari, G.; Palchetti, S.; Pozzi, D.; Mahmoudi, M.; Laganà, A., In vivo protein 
corona patterns of lipid nanoparticles. Royal Society of Chemistry Advances 2017, 7, 1137-1145. 
25. Bertrand, N.; Grenier, P.; Mahmoudi, M.; Lima, E. M.; Appel, E. A.; Dormont, F.; Lim, J.-M.; Karnik, R.; 
Langer, R.; Farokhzad, O. C., Mechanistic understanding of in vivo protein corona formation on polymeric 
nanoparticles and impact on pharmacokinetics. Nature Communications 2017, 8, 1-8. 
26. Hajipour, M. J.; Laurent, S.; Aghaie, A.; Rezaee, F.; Mahmoudi, M., Personalized protein coronas: a “key” 
factor at the nanobiointerface. Biomaterials Science 2014, 2 (9), 1210-1221. 
27. Anderson, N. L.; Anderson, N. G., The Human Plasma Proteome History, Character, and Diagnostic 
Prospects. Molecular & Cellular Proteomics 2002, 1 (11), 845-867. 
28. Liu, R.; Jiang, W.; Walkey, C. D.; Chan, W. C. W.; Cohen, Y., Prediction of nanoparticles-cell association 
based on corona proteins and physicochemical properties. Nanoscale 2015, 7, 9664-9675. 
29. Palchetti, S.; Digiacomo, L.; Pozzi, D.; Peruzzi, G.; Micarelli, E.; Mahmoudi, M.; Caracciolo, G., 
Nanoparticles-cell association predicted by protein corona fingerprints. Nanoscale 2016, 8, 12755-12763. 
30. Walkey, C. D.; Olsen, J. B.; Song, F.; Liu, R.; Guo, H.; Olsen, D. W. H.; Cohen, Y.; Emili, A.; Chan, W. C. 
W., Protein Corona Fingerprinting Predicts the Cellular Interaction of Gold and Silver Nanoparticles. ACS Nano 
2014, 8 (3), 2439-2455. 
31. Kamath, P.; Fernandez, A.; Giralt, F.; Rallo, R., Predicting Cell Association of Surface-Modified 
Nanoparticles Using Protein Corona Structure - Activity Relationships (PCSAR). Current Topics in Medicinal 
Chemistry 2015, 15 (18), 1930-1937. 
26 
 
32. Lin, Z.; Monteiro-Riviere, N. A.; Kannan, R.; Riviere, J. E., A computational framework for interspecies 
pharmacokinetics, exposure and toxicity assessment of gold nanoparticles. Nanomedicine (Lond.) 2016, 11 (2), 
107-119. 
33. Sahneh, F. D.; Scoglio, C. M.; Monteiro-Riviere, N. A.; Riviere, J. E., Predicting the impact of biocorona 
formation kinetics on interspecies extrapolations of nanoparticle biodistribution modeling. Nanomedicine (Lond.) 
2015, 10 (1), 25-33. 
34. Walkey, C. D.; Chan, W. C. W., Understanding and controlling the interaction of nanomaterials with 
proteins in a physiological environment. Chemical Society Reviews 2012, 41, 2780-2799. 
35. Shah, A. S.; Tan, L.; Long, J. L.; Davidson, W. S., Proteomic diversity of high density lipoproteins: our 
emerging understanding of its importance in lipid transport and beyond. Journal of Lipid Research 2013, 54 (10), 
2575-2585. 
36. Davidson, W. S. Davidson Lab Webpage: Lipoprotein Proteome Watch. www.DavidsonLab.com 
(accessed July 17, 2018). 
37. Lundqvist, M.; Stigler, J.; Elia, G.; Lynch, I.; Cedervall, T.; Dawson, K. A., Nanoparticle size and surface 
properties determine the protein corona with possible implications for biological impacts. Proceedings of the 
National Academy of Sciences 2008, 105 (38), 14265-14270. 
38. Tan, J.; Shah, S.; Thomas, A.; Ou-Yang, H. D.; Liu, Y., The influence of size, shape and vessel geometry 
on nanoparticle distribution. Microfluid Nanofluidics 2013, 14 (1-2), 77-87. 
39. Shah, S.; Liu, Y.; Hu, W.; Gao, J., Modeling Particle Shape-Dependent Dynamics in Nanomedicine. 
Journal of Nanoscience and Nanotechnology 2011, 11 (2), 919-928. 
40. Lee, S.-Y.; Ferrari, M.; Decuzzi, P., Shaping nano-/micro-particles for enhanced vascular interaction in 
laminar flows. Nanotechnology 2009, 20 (49), 1-11. 
41. Vahidkhaha, K.; Bagchi, P., Microparticle shape effects on margination, near-wall dynamics and adhesion 
in a three-dimensional simulation of red blood cell suspension. Soft Matter 2015, 11 (11), 2097-2109. 
42. Lee, T.-R.; Choi, M.; Kopacz, A. M.; Yun, S.-H.; Liu, W. K.; Decuzzi, P., On the near-wall accumulation of 
injectable particles in the microcirculation: smaller is not better. Scientific Reports 2013, 3, 1-8. 
43. Charoenphol, P.; Mocherla, S.; Bouis, D.; Namdee, K.; Pinsky, D. J.; Eniola-Adefeso, O., Targeting 
therapeutics to the vascular wall in atherosclerosis–Carrier size matters. Atherosclerosis 2011, 217 (2), 364-370. 
44. Toy, R.; Hayden, E.; Shoup, C.; Baskaran, H.; Karathanasis, E., Effect of Particle Size, Density and Shape 
on Margination of Nanoparticles in Microcirculation. Nanotechnology 2011, 22 (11), 1-18. 
45. D'Apolito, R.; Tomaiuolo, G.; Taraballi, F.; Minardi, S.; Kirui, D.; Liu, X.; Cevenini, A.; Palomba, R.; Ferrari, 
M.; Salvatore, F.; Tasciotti, E.; Guido, S., Red blood cells affect the margination of microparticles in synthetic 
microcapillaries and intravital microcirculation as a function of their size and shape. Journal of Controlled Release 
2015, 217, 263-272. 
46. Thompson, A. J.; Mastria, E. M.; Eniola-Adefeso, O., The margination propensity of ellipsoidal 
micro/nanoparticles to the endothelium in human blood flow. Biomaterials 2013, 34 (23), 5863-5871. 
47. Decuzzi, P.; Ferrari, M., The adhesive strength of non-spherical particles mediated by specific interactions. 
Biomaterials 2006, 27, 5307-5314. 
48. Gentile, F.; Curcio, A.; Indolfi, C.; Ferrari, M.; Decuzzi, P., The margination propensity of spherical particles 
for vascular targeting in the microcirculation. Journal of Nanobiotechnology 2008, 6 (9), 1-9. 
27 
 
49. Decuzzi, P.; Lee, S.; Bhushan, B.; Ferrari, M., A Theoretical Model for the Margination of Particles within 
Blood Vessels. Annals of Biomedical Engineering 2005, 33 (2), 179-190. 
50. Kumari, S.; Swetha, M. G.; Mayor, S., Endocytosis unplugged: multiple ways to enter the cell. Cell 
Research 2010, 20, 256-275. 
51. Jiang, W.; Kim, B. Y. S.; Rutka, J. T.; Chan, W. C. W., Nanoparticle-mediated cellular response is size-
dependent. Nature Nanotechnology 2008, 3, 145-150. 
52. Lu, F.; Wu, S.-H.; Hung, Y.; Mou, C.-Y., Size Effect on Cell Uptake in Well-Suspended, Uniform 
Mesoporous Silica Nanoparticles. Small 2009, 5 (12), 1408-1413. 
53. Varela, J. A.; Bexiga, M. G.; Åberg, C.; Simpson, J. C.; Dawson, K. A., Quantifying size-dependent 
interactions between fluorescently labeled polystyrene nanoparticles and mammalian cells. Journal of 
Nanobiotechnology 2012, 10 (39), 1-6. 
54. Wang, S.-H.; Lee, C.-W.; Chiou, A.; Wei, P.-K., Size-dependent endocytosis of gold nanoparticles studied 
by three-dimensional mapping of plasmonic scattering images. Journal of Nanobiotechnology 2010, 8 (33), 1-13. 
55. Liu, X.; Huang, N.; Li, H.; Jin, Q.; Ji, J., Surface and Size Effects on Cell Interaction of Gold Nanoparticles 
with Both Phagocytic and Nonphagocytic Cells. Langmuir 2013, 29, 9138-9148. 
56. Ma, X.; Wu, Y.; Jin, S.; Tian, Y.; Zhang, X.; Zhao, Y.; Yu, L.; Liang, X.-J., Gold Nanoparticles Induce 
Autophagosome Accumulation through Size-Dependent Nanoparticle Uptake and Lysosome Impairment. ACS 
Nano 2011, 5 (11), 8629-8639. 
57. Sabuncu, A. C.; Grubbs, J.; Qian, S.; Abdel-Fattah, T. M.; Stacey, M. W.; Beskok, A., Probing nanoparticle 
interactions in cell culture media. Colloids and Surfaces B: Biointerfaces 2012, 95, 96-102. 
58. Oh, J.-M.; Choi, S.-J.; Lee, G.-E.; Kim, J.-E.; Choy, J.-H., Inorganic Metal Hydroxide Nanoparticles for 
Targeted Cellular Uptake Through Clathrin-Mediated Endocytosis. Chemistry - An Asian Journal 2009, 4, 67-73. 
59. Kim, I.-Y.; Joachim, E.; Choi, H.; Kim, K. K., Toxicity of silica nanoparticles depends on size, dose, and 
cell type. Nanomedicine: Nanotechnology, Biology and Medicine 2015, 11 (6), 1407-1416. 
60. Clift, M. J. D.; Rothen-Rutishauser, B.; Brown, D. M.; Duffin, R.; Donaldson, K.; Proudfoot, L.; Guy, K.; 
Stone, V., The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine 
macrophage cell line. Toxicology and Applied Pharmacology 2008, 232 (3), 418-427. 
61. Huang, J.; Bu, L.; Xie, J.; Chen, K.; Cheng, Z.; Li, X.; Chen, X., Effects of Nanoparticle Size on Cellular 
Uptake and Liver MRI with Polyvinylpyrrolidone-Coated Iron Oxide Nanoparticles. ACS Nano 2010, 4 (12), 7151-
7160. 
62. dos-Santos, T.; Varela, J.; Lynch, I.; Salvati, A.; Dawson, K. A., Quantitative Assessment of the 
Comparative Nanoparticle-Uptake Efficiency of a Range of Cell Lines. Small 2011, 7 (23), 3341-3349. 
63. Beduneau, A.; Ma, Z.; Grotepas, C. B.; Kabanov, A.; Rabinow, B. E.; Gong, N.; Mosley, R. L.; Dou, H.; 
Boska, M. D.; Gendelman, H. E., Facilitated Monocyte-Macrophage Uptake and Tissue Distribution of 
Superparmagnetic Iron-Oxide Nanoparticles. PLoS One 2009, 4 (2), e4343. 
64. Kunzmann, A.; Andersson, B.; Vogt, C.; Feliu, N.; Ye, F.; Gabrielsson, S.; Toprak, M. S.; Buerki-Thurnherr, 
T.; Laurent, S.; Vahter, M.; Krug, H.; Muhammed, M.; Scheynius, A.; Fadeel, B., Efficient internalization of silica-
coated iron oxide nanoparticles of different sizes by primary human macrophages and dendritic cells. Toxicology 
and Applied Pharmacology 2011, 253 (2), 81-93. 
28 
 
65. Kettler, K.; Giannakou, C.; Jong, W. H. d.; Hendriks, A. J.; Krystek, P., Uptake of silver nanoparticles by 
monocytic THP-1 cells depends on particle size and presence of serum proteins. Journal of Nanoparticle Research 
2016, 18 (9), 286. 
66. Barua, S.; Yoo, J.-W.; Kolhar, P.; Wakankar, A.; Gokarn, Y. R.; Mitragotri, S., Particle shape enhances 
specificity of antibody-displaying nanoparticles. Proceedings of the National Academy of Sciences 2013, 110 (9), 
3270-3275. 
67. Huang, X.; Teng, X.; Chen, D.; Tang, F.; He, J., The effect of the shape of mesoporous silica nanoparticles 
on cellular uptake and cell function. Biomaterials 2010, 31 (3), 438-448. 
68. Chithrani, B. D.; Ghazani, A. A.; Chan, W. C. W., Determining the Size and Shape Dependence of Gold 
Nanoparticle Uptake into Mammalian Cells. Nano Letters 2006, 6 (4), 662-668. 
69. Chithrani, B. D.; Chan, W. C. W., Elucidating the Mechanism of Cellular Uptake and Removal of Protein-
Coated Gold Nanoparticles of Different Sizes and Shapes. Nano Letters 2007, 7 (6), 1542-1550. 
70. Champion, J. A.; Mitragotri, S., Role of target geometry in phagocytosis. Proceedings of the National 
Academy of Sciences 2006, 103 (13), 4930-4934. 
71. Padmore, T.; Stark, C.; Turkevich, L. A.; Champion, J. A., Quantitative analysis of the role of fiber length 
on phagocytosis and inflammatory response by alveolar macrophages. Biochimica et Biophysica Acta 2017, 1861 
(2), 58-67. 
72. Geng, Y.; Dalhaimer, P.; Cai, S.; Tsai, R.; Tewari, M.; Minko, T.; Discher, D. E., Shape effects of filaments 
versus spherical particles in flow and drug delivery. Nature Nanotechnology 2007, 2, 249-255. 
73. Schinwald, A.; Murphy, F. A.; Prina-Mello, A.; Poland, C. A.; Byrne, F.; Movia, D.; Glass, J. R.; Dickerson, 
J. C.; Schultz, D. A.; Jeffree, C. E.; MacNee, W.; Donaldson, K., The Threshold Length for Fiber-Induced Acute 
Pleural Inflammation: Shedding Light on the Early Events in Asbestos-Induced Mesothelioma. Toxicological 
Sciences 2012, 128 (2), 461-470. 
74. Murphy, F. A.; Schinwald, A.; Poland, C. A.; Donaldson, K., The mechanism of pleural inflammation by 
long carbon nanotubes: interaction of long fibres with macrophages stimulates them to amplify pro-inflammatory 
responses in mesothelial cells. Particle and Fibre Toxicology 2012, 9 (8), 1-15. 
75. Huang, X.; Li, L.; Liu, T.; Hao, N.; Liu, H.; Chen, D.; Tang, F., The Shape Effect of Mesoporous Silica 
Nanoparticles on Biodistribution, Clearance, and Biocompatibility in Vivo. ACS Nano 2011, 5 (7), 5390-5399. 
76. Arnida; Janát-Amsbury, M. M.; Ray, A.; Peterson, C. M.; Ghandehari, H., Geometry and surface 
characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages. European Journal 
of Pharmaceutics and Biopharmaceutics 2011, 77 (3), 417-423. 
77. Bartneck, M.; Keul, H. A.; Singh, S.; Czaja, K.; Bornemann, J.; Bockstaller, M.; Moeller, M.; Zwadlo-
Klarwasser, G.; Groll, J., Rapid uptake of gold nanorods by primary human blood phagocytes  and 
immunomodulatory effects of surface chemistry. ACS Nano 2010, 4 (6), 3073-3086. 
78. Wisse, E.; Jacobs, F.; Topal, B.; Frederik, P.; Geest, B. D., The size of endothelial fenestrae in human liver 
sinusoids: implications for hepatocyte-directed gene transfer. Gene Therapy 2008, 15, 1193-1199. 
79. Chen, L.-T.; Weiss, L., The Role of the Sinus Wall in the Passage of Erythrocytes Through the Spleen. 
Blood 1973, 41 (4), 529-537. 
80. Ohlson, M.; Sörensson, J.; Haraldsson, B., A gel-membrane model of glomerular charge and size 
selectivity in series. American Journal of Physiology - Renal Physiology 2001, 280 (3), F396-F405. 
29 
 
81. Decuzzi, P.; Godin, B.; Tanaka, T.; Lee, S.-Y.; Chiappini, C.; Liu, X.; Ferrari, M., Size and shape effects in 
the biodistribution of intravascularly injected particles. Journal of Controlled Release 2010, 141 (3), 320-327. 
82. Christian, D. A.; Cai, S.; Garbuzenko, O. B.; Harada, T.; Zajac, A. L.; Minko, T.; Discher, D. E., Flexible 
Filaments for in vivo Imaging and Delivery: Persistent Circulation of Filomicelles Opens the Dosage Window for 
Sustained Tumor Shrinkage. Molecular Pharmaceutics 2009, 6 (5), 1343-1352. 
83. Kaga, S.; Truong, N. P.; Esser, L.; Senyschyn, D.; Sanyal, A.; Sanyal, R.; Quinn, J. F.; Davis, T. P.; 
Kaminskas, L. M.; Whittaker, M. R., Influence of Size and Shape on the Biodistribution of Nanoparticles Prepared 
by Polymerization-Induced Self-Assembly. Biomacromolecules 2017, 18 (12), 3963-3970. 
84. Müllner, M.; Dodds, S. J.; Nguyen, T.-H.; Senyschyn, D.; Porter, C. J. H.; Boyd, B. J.; Caruso, F., Size 
and Rigidity of Cylindrical Polymer Brushes Dictate Long Circulating Properties In Vivo. ACS Nano 2015, 9 (2), 
1294-1304. 
85. Black, K. C. L.; Wang, Y.; Luehmann, H. P.; Cai, X.; Xing, W.; Pang, B.; Zhao, Y.; Cutler, C. S.; Wang, L. 
V.; Liu, Y.; Xia, Y., Radioactive 198Au-Doped Nanostructures with Different Shapes for In Vivo Analyses of Their 








































2.1  Abstract 
 
Nanoparticles introduced into the bloodstream are exposed to thousands of proteins that are competing 
for their surfaces. During transport, this competition changes the amount and class of proteins that are bound to 
the nanoparticle surface. High density lipoproteins (HDLs) have been shown to bind nanoparticle surfaces of 
different sizes and chemistries, but quantitative values are lacking. Bound HDLs could change the biodistribution of 
nanoparticles if the interaction is stable and HDLs retain their functionality.  
We determined equilibrium binding parameters for HDLs and nanoparticles using isothermal titration 
calorimetry, gel electrophoresis and a quantitative model of protein-sphere interactions. We used polystyrene 
spheres – PS, PS-COOH, and PS-NH2 – as model nanoparticles. Apolipoprotein A-I – the main structural protein 
of HDLs – was shown to bind nanoparticles with moderate binding affinities in spite of competition from other 
plasma proteins. Isothermal titration calorimetry and exploration of the secondary structure of lipoproteins indicated 
that conformational states of lipoproteins could play a role in determining their strength of binding. 
Our in vivo investigations with SCARBI-/- mice demonstrated the involvement of lipoprotein bound 
nanoparticles and lipoprotein receptors in nanoparticle biodistribution. We also determined from measurements of 
plasma HDL and LDL/VLDL cholesterol content that cholesterol metabolism was important to the uptake and 
biodistribution of injected polystyrene nanoparticles. In addition, we found that female and male mice have 
differences in relation to lipid metabolism which translated into different biodistribution profiles. Overall, this shows 
that lipid and lipoprotein metabolism are indeed important in nanoparticle drug delivery and this would have 




2.2  Introduction 
 
 Over the last decades, nanotechnology-based therapeutics have been used for the treatment of various 
diseases, however, biological barriers have precluded the effectiveness of such drug delivery systems with poor 
drug biodistribution or accumulation at diseased sites being one of the major challenges.1-4 Nanoparticle-based 
drug delivery systems that are administered intravenously to a patient enter the bloodstream and encounter blood 
proteins and biomolecules that vie for a position on the surface of the nanoparticles. Surface coverage and the 
composition of the adsorbed entities is determined by their respective affinities for the nanoparticle.5-6  
 Many research studies have revealed that lipoproteins constitute a major component of the biomolecular 
corona mass surrounding different nanoparticles exposed to blood or plasma proteins.7-13 In particular, high-
density lipoproteins (HDLs) or its major associated apolipoproteins have been demonstrated to bind nanoparticles 
in vitro with high affinity. For instance, apolipoproteinA-I (ApoA-I) – the main structural protein of HDLs – has been 
shown to bind polystyrene nanoparticles, PS (24 nm) and PS-COOH (28 nm), with affinity (Kd) values of 360 nM 
and 60 nM respectively.14 Hydroxyethyl starch (HES) nanocapsules possessing different functionalities were 
shown to bind ApoA-I with Kd values of ~3 nM, ~5.3 nM, and ~185 nM for HES (275 ± 28 nm), HES-COOH (200 
± 20 nm), and HES-NH2 (256 ± 26 nm) respectively.15 Reconstituted HDL particles have also displayed high 
binding affinities to 70 nm N-iso-propylacrylamide/N-tert-butylacrylamide copolymer nanoparticles with a Kd value 
of 1 nM.16 Notwithstanding, quantitative values are still lacking for studies that measure the binding affinity of HDLs, 
or its main structural proteins, for nanoparticles that are exposed to whole plasma. In order to achieve this aim, we 
investigated the binding of lipoproteins in mouse plasma to polystyrene nanoparticles of different surface 
33 
 
chemistries. We show that binding of lipoproteins to these nanoparticles was still fairly strong (Kd in micromolar 
range) despite competition from numerous proteins or biomolecules usually present in plasma. 
 Taking into consideration the binding of lipoproteins to nanoparticles, it is conceivable that lipoproteins 
could potentially change the course of injected nanoparticles to lipoprotein receptors (e.g. scavenger receptor class 
B I) in the body. Because lipoprotein receptors can be found widely distributed throughout tissues or major organs 
of the body (liver, lung, spleen, heart and kidney),17 this could have significant consequences for nanoparticle drug 
delivery applications since delivery to potential targets would dwindle. Toxicity also becomes a major concern. 
Relevant in vivo models are thus needed to examine the distribution of nanoparticles in the body following binding 
to plasma lipoproteins in circulation. We address this issue by employing scavenger receptor class B I (SCARBI) 
mouse models that alter lipoprotein uptake, and clodronate liposomal formulations for macrophage depletion. Our 
findings demonstrate that nanoparticle distribution is indeed affected by lipoprotein receptor binding; and 
interestingly, there were differences in nanoparticle uptake and biodistribution between male and female genders 
of which lipid metabolism was implicated in the understanding of the overall observed differences. 
 
2.3  Materials and Methods 
 
2.3.1  Materials 
 
50 nm PS (08691-10) and PS-COOH (15913-10) nanoparticles were purchased from Polysciences, Inc., United 
States and used as received. 50 nm PS-NH2 were purchased from Bangs Laboratories, United States and used as 
received. 10X phosphate buffered saline powder concentrate (BP665-1), bovine serum albumin (BSA) fraction V 
(BP-1605-100), Coomassie brilliant blue R-250 (BP101-25), Tris-HCl (BP-153-300), glycerol (BP229-1), sodium 
chloride (BP358-1) and EDTA (S311) were all purchased from Fisher Scientific, United States. β-mercaptoethanol 
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(M3148) was purchased from Sigma-Aldrich, United States. Sodium dodecyl sulfate (SDS) sample buffer was 
formulated (250 mM Tris-HCl pH 6.8, 10% SDS, 30% Glycerol, 5% β-mercaptoethanol, 0.02% bromophenol 
blue). Precast protein gels (10-well NuPAGE 12% Bis-Tris and 15-well NuPAGE 4-12% Bis-Tris), 20X NuPAGE 
MOPS SDS running buffer and 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindotricarbocyanine Iodide (DiR) dye were 
purchased from Thermo Fisher Scientific, United States.  
Mouse plasma (GTX73236) was purchased from Genetex, Inc., United States and human HDLs (361-10) were 
purchased from Lee Biosolutions, Inc., United States. Thyroglobulin, ovalbumin, carbonic anhydrase, 
ribonuclease, aprotinin, dextran 2000 were all purchased from GE Healthcare, United States. MP Biomedicals 
gamma globulin from bovine plasma and BD Vacutainer plasma separation tubes (PST) coated with lithium 
heparin were purchased from Fisher Scientific, United States. PageRuler Plus Prestained 10-250kDa Protein 
Ladder was purchased from Thermo Fisher Scientific, United States. 
 
2.3.2  In Vitro Binding of Plasma Proteins to Polystyrene Nanoparticles 
 
Mouse plasma was thawed in a water bath maintained at 37°C and centrifuged at 3,000 rpm for 5 min at 4°C 
(Sorvall Legend XTR Centrifuge, Thermo Fisher Scientific, Germany). The supernatant was collected, transferred to 
new tubes and re-spun at 13,300 rpm (17,000 xg) for 3 min at 4°C (accu Spin Micro 17, Fisher Scientific, 
Germany). Concentrations of polystyrene nanoparticles (5.85 x 1012 particles/ml, calculated based on 
manufacturer’s specifications) were chosen such that there were no appreciable depletion effects from ApoA-I 
binding to the nanoparticles. Different mouse plasma dilutions were made and incubated with the polystyrene 
nanoparticles at 4°C for 2 hours on an orbital shaker (Orbitron Rotator II, Boekel Scientific, United States). 
Respective control samples were also incubated concurrently under the same conditions, and all dilutions for 
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mouse plasma were done with 1X PBS. After incubation, the samples were centrifuged (Beckman Optima LE-80K 
Ultracentrifuge, Beckman Coulter Inc., United States) at 4°C and at a speed of 40,000 rpm (Type 80 Ti rotor, 
150,528 xgmax) for 20 min to separate unbound proteins from the nanoparticles. The solid nanoparticle-protein 
pellet was washed with 1X PBS and resuspended in SDS buffer. After addition of SDS sample buffer to the 
samples containing the nanoparticle-protein pellet and also the supernatant containing unbound proteins, they 
were incubated at 95°C for 10 mins. Following protein desorption and denaturation, the samples were then loaded 
onto a protein gel and run in 1X MOPS running buffer at 200 V for 50 min. For each gel, diluted mouse plasma at 
1/20 X was used as an in-gel standard. The 1/20 X mouse plasma was calibrated for both 10-well and 15-well 
gels by using several known concentrations of BSA (Appendix A.2). Relative density values from the known 
albumin protein bands and all other protein bands were estimated using ImageJ software (http://rsbweb.nih.gov/ij) 
after staining with Coomassie blue. All of the gels were set up to include controls for both the supernatant and the 
nanoparticle-protein pellet samples, and dilutions from the sample buffer was accounted for when calculating the 
amount of proteins from needed sample bands. These in vitro experiments were carried out in triplicates. 
The above procedure was applied to another experiment, but incubations were carried out with constant mouse 
plasma or human HDL (hHDL) concentrations and increasing nanoparticle concentrations. These experiments 
were carried out once. 
 
2.3.3  HDL Isolation by Anion Exchange Chromatography  
 
Two or three milliliters of mouse plasma was passed through a sterile polyethersulfone 0.22 µm filter (Millex-GP, 
Millipore) and introduced into a 50 ml Superloop (GE Healthcare, United States) column on an ÄKTApurifier 10 
FPLC system maintained at 4°C. The mouse plasma was allowed to equilibrate in the starting buffer (1 mM EDTA, 
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20 mM Tris-HCl; pH 8.6) and then injected via the Superloop into an anion exchange column (Source 15Q, GE 
Healthcare, United States). The sample was processed at a flow rate of 1.2 ml/min and eluted (1 mM EDTA, 500 
mM NaCl and 20 mM Tris-HCl; pH 8.4) as 1 ml fractions on a Frac-920 (GE Healthcare, United States) fraction 
collector modified to include 1.5 ml microcentrifuge tubes. Peaked fractions were run on a protein gel to determine 
purity and where to collect fractions containing HDLs. Subsequently, HDL peaked fractions were pooled and 
dialyzed against 1X PBS at 4°C.  
 
2.3.4  Protein Identification by Mass Spectrometry 
 
Bands of interest that were excised from SDS-PAGE gels and in-gel digestion was performed with trypsin 
according to a protocol by Shevchenko and coworkers.18 The resulting peptide mixtures were separated with an 
UltiMate 3000 RSLCnano system (Thermo Fisher Scientific, United States) via precolumn concentration and an 
EASY-spray ionization source (Thermo Fisher Scientific, United States). 10 µl of the sample was loaded on the a 
PepMap C18 (Thermo Fisher Scientific, United States) precolumn using 98:2 (v/v) water: acetonitrile. This solvent 
was also used to desalt the sample for 10 min following the start of the run. After 10 min, the precolumn was back 
flushed with 100% water with 0.1% formic acid. The separation used an EASY-spray column (ES800, Thermo 
Fisher Scientific, United States) over the course of 60 min. Chromatography solutions (solvent A: 100% water with 
0.1% formic acid; solvent B:100% acetonitrile with 0.1% formic acid) were used to deliver the 60 min gradient. 
The gradient is as follows: t = 0 min 100% A, 0% B; t = 10 min 100% A, 0% B; t = 35 min 5% A, 95% B; t = 45 
min 5% A, 95% B; t = 45.1 min 100% A, 0% B; t = 60 min 100% A, 0% B. The column was kept at 40 °C.  
A Thermo Scientific Q Exactive Orbitrap mass spectrometer was used to collect data. Data was collected in positive 
mode with the following ionization conditions: spray voltage 1.50 kV; capillary temperature 300°C. A full scan/data 
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dependent Top N analysis was performed to collected full scan data and fragmentation data of the most abundant 
m/z eluting the column. Mass spectrometer settings for the full scan were: resolution 70,000; automatic gain 
control 3x106 ions; max IT time 100 ms; m/z range 200-2000. Mass spectrometer settings for the data dependent 
acquisition were: resolution 17,500; automatic gain control 1x105 ions; max IT time 50 ms; loop count 12; isolation 
window 1 m/z; normalized collisional energy 30; dynamic exclusion 10.0 s.   
Following data collection, the MaxQuant software was used to match detected parent masses and fragments to an 
in silico digested FASTA proteome with an error window of 5 ppm. 
 
2.3.5  Gel Filtration Chromatography 
 
hHDL and pooled fractions of mouse HDL (mHDL) from anion exchange chromatography were applied to a gel 
filtration column to estimate their molecular weights. A Superose 12 10/300 GL (GE Healthcare, United States) size 
exclusion column on an ÄKTA FPLC system was utilized. The column was equilibrated (50 mM phosphate, 0.15 
M NaCl, pH 7.2) and then calibrated using the following molecular mass markers: thyroglobulin (670 kDa), 
gamma globulin (150 kDa), ovalbumin (44 kDa), ribonuclease (13.7 kDa), carbonic anhydrase (29 kDa) and 
aprotinin (6.5 kDa). Blue dextran 2000 was used to determine the column void volume. The gel phase distribution 
coefficient (Kav) value was calculated as: (elution volume – column void volume) / (geometric column volume – 
column void volume). A calibration curve of Kav versus logarithm of the molecular weight (log Mr) was plotted to 







2.3.6  Isothermal Titration Calorimetry (ITC) 
 
Experiments were carried out with a VP-ITC microcalorimeter (TA instruments, United States) at a temperature of 
25°C and stirring rate of 300 rpm. Ultrapure Milli-Q water was used as a reference solution for the titrations. In 
order to minimize pH change during experiments, the studies were performed at neutral pH in aqueous solution. 
Lipoproteins (mHDL and hHDL) and polystyrene nanoparticles (PS, PS-COOH, PS-NH2) were dialyzed against 
Milli-Q water, and experiments consisted of consecutive additions of lipoprotein solutions (1.92 mg/ml) from the 
syringe into nanoparticle solution (~1.2 x 10-5 mM) located in the cell of volume 1.451 ml. Lipoprotein solutions 
were added as 10 ul injections and the resulting data of heat against molar ratio were analyzed with an 
independent binding site model19 using Microcal Origin 7.0 software. The first 2 µl injection was discarded 
because of diffusion of HDL before the initiation of the experiment. Appendix A.1 contains details of the model. 
 
2.3.7  Preparation of DiR-loaded PS-COOH Nanoparticles 
 
PS-COOH with DiR was prepared by a modified solvent-diffusion method.20 Briefly, a solution containing the 
concentrated DiR (2.5 mg/ml in methanol) was added into 600 µl of PS-COOH (25 mg/ml) nanoparticle 
suspension. The solution was mixed and incubated for 15 min followed by dialysis (12 – 14 K MWCO) in 1X 
PBS. The same procedure was used for all preparations of PS-COOH-DiR labeled nanoparticles and the 
concentration of DiR was determined by UV-VIS from a DiR calibration curve. Particle size distribution of the PS-
COOH-DiR nanoparticles was determined with DLS to ensure that the size distribution after labeling was relatively 






2.3.8  In Vivo Studies 
 
Animal experiments were conducted using institutionally approved protocols by the Institutional Animal 
Care and Use Committee (IACUC) at the University of Tennessee, Knoxville.  
Mice that are wild-type and homozygous null for SCARBItm1Kri were bred from six female and three male mice that 
are heterozygous for SCARBItm1Kri (stock# 003379, JAX Laboratory, United States). The breeding pair consisted of 
two female mice for one male mouse in a cage. All animals had free access to drinking water and a low-fat diet 
(D12450B, Research Diets, Inc., United States), and their housing facility was maintained at room temperature with 
regular day and night cycles. In a typical experiment, mice were injected intravenously via the tail vein with 200 µl 
of either clodronate liposomes or control liposomes (Liposoma B.V., Netherlands). Female mice had an average 
weight of 20.56 g (± 1.52) while male mice had an average weight of 22.66 g (± 2.06) (Appendix A.10). After 24 
hours, mice were injected with either 100 µl of 1X PBS, DiR dye in 1X PBS or PS-COOH-DiR dyed nanoparticles. 
Twenty-four hours later, blood samples were collected via cardiac puncture with the mice under isoflurane 
anesthesia. Blood samples were collected into lithium heparin coated PST and centrifuged to obtain mouse 
plasma. Separated plasma samples were stored on ice for the duration of an experiment before freezing at -80°C 
for longer-term storage. At the end of blood collection and plasma separation, mice organs were harvested, and 
fluorescent images were obtained using a Vivo Vision IVIS Lumina (Caliper Co., United States) imaging system. 
 
2.3.9  PCR Screening for Mice Genotype 
 
Mouse tail snips were performed, and genomic DNA extractions were carried out according to manufacturer’s 
protocol using DirectAmp tissue genomic DNA amplification kit (Denville Scientific, United States). The following 
stock primers were used as recommended by JAX Laboratory for SCARBItm1kr1: oIMR7768 wild-type forward, 5’-
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ATC TCA GCC TTA GGC CCT GT-3’; oIMR7769 common, 5’-TCA AAC CCT GTG ACA ACA GC-3’; and 
oIMR7770 mutant forward, 5’-ATA GAT TCG CCC TTG TGT CC-3’. Stock primers were diluted to 100 pmoles/µl 
and then a fresh primer mix was made by diluting all primers to 10 pmoles/µl. The recipe for PCR amplification 
consisted of 4 µl of DNA extract, 1 µl of primer mix, 10 µl of Hot-Start Taq mastermix (Denville Scientific, United 
States) and 5 µl of water. PCR was carried out with an Eppendorf Mastercycler X50a (Eppendorf, Germany) under 
the following cycling conditions: 94°C for 4 min, (94°C for 20 s, 65°C for 20 s (lower by 0.5°C every cycle), 68°C 
for 20 s) 10 cycles, (94°C for 20 s, 60°C for 20 s, 72°C for 20 s) 28 cycles, 72°C for 2 min and hold at 4°C. 
Following the run, the PCR products were run on a 2% agarose gel at 100 V for 30 min. PCR products that were 
wild-type, heterozygous and mutant would have the following band sizes: 262 bp; 140 bp and 262 bp; and 140 bp 
respectively (Appendix A.9). exACTGene 50 bp mini DNA ladder (Fisher Scientific, United States) was used as the 
size marker. 
 
2.3.10  HDL and LDL/VLDL Cholesterol Quantification 
 
HDL and LDL/VLDL cholesterol quantification of mouse plasma was performed using an HDL and LDL/VLDL 
cholesterol assay kit (Abcam, United Kingdom). Optical density measurements were carried out at 570 nm. 
 
2.4  Results and Discussion 
 
2.4.1  Measurement of Binding Parameters by Gel Electrophoresis 
 
The law of mass action was used to determine the binding of ApoA-I to the different polystyrene nanoparticles. We 
employed a simplified binding model where a nanoparticle was considered to have identical independent binding 
sites such that the binding of a protein to the nanoparticle does not influence subsequent binding steps. For the 
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sake of simplicity, the final derivations shown here are given in its reduced form; the more complicated and exact 
step-by-step binding approach can be found elsewhere.21  
[𝑁] + [𝑃] ⇌ [𝑁𝑃]                                                                                                                       (2.1) 
 
[𝑁𝑇] = [𝑁𝑃] + [𝑁]                                                                                                                     (2.2) 
 
[𝑃𝑇] = [𝑁𝑃] + [𝑃]                                                                                                                       (2.3) 
 
where [N] and [P] are the concentrations of free nanoparticle and protein respectively. [NT] and [PT] are the total 
concentrations of nanoparticle and protein respectively while [NP] is the nanoparticle-protein complex 
concentration 
𝑅𝑎𝑡𝑒 𝑜𝑓 𝑓𝑜𝑟𝑤𝑎𝑟𝑑 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 =  𝐾𝑓 ∙ [𝑁][𝑃]                                                                         (2.4) 
 
𝑅𝑎𝑡𝑒 𝑜𝑓 𝑟𝑒𝑣𝑒𝑟𝑠𝑒 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 =  𝐾𝑟 ∙ [𝑁𝑃]                                                                              (2.5) 
 
Equating Eqn. (2.4) with Eqn. (2.5) and finding the ratio of the forward (Kf) and reverse (Kr) rate constants gives the 
expression for the association (Ka) binding constant while the inverse produces the dissociation (Kd) binding 
constant, 
𝐾𝑎 =  
[𝑁𝑃]
[𝑁][𝑃]
                                                                                                                                (2.4) 
 
𝐾𝑑 =  
[𝑁][𝑃]
[𝑁𝑃]
                                                                                                                                (2.5) 
 
If we consider the nanoparticle surface as having only one binding site, then the simple 1:1 binding from the 
interaction of protein with the binding site in Eqn. (2.1) will yield the concentration of bound protein [NP]. Equating 








                                                                                                                        (2.6) 
 
We however make the assumption that the polystyrene nanoparticle surface consists of multiple independent non-
interacting binding sites. Therefore, if multiple independent and identical sites are on the polystyrene nanoparticle 
then the total amount of binding sites becomes, 
𝑛[𝑁𝑇] = [𝑁𝑃] + [𝑁]                                                                                                                   (2.7) 
 













                                                                            (2.8) 
 
but now bound protein [NP] incorporates all of the partially saturated forms of the nanoparticle-protein complex, 
 






+. . . +
[𝑁𝑇][𝑃]
𝐾𝑑𝑛 + [𝑃]
        (2.9) 
 
where n different sites can be occupied by the protein with the respective binding constant  
A plot of ApoA-I that is bound to the nanoparticles versus free ApoA-I yields a hyperbolic curve where the 
binding affinity (Kd) can be obtained at half fractional saturation (n/2). This approach can be taken given that there 
are no considerable depletion effects from the protein binding to the nanoparticles, that is, [P] is approximately [PT] 
at all concentrations used for the experiments.22 In order to check for this, the unbound ApoA-I in the test 
supernatant and the ApoA-I in control supernatant were compared. Our results from measuring the density of the 
ApoA-I protein bands in the supernatant show that our assumptions are valid (Appendix A.3-1(A) – A.3-3(A)) and 
further calculations were not needed to account for depletion effects. Kd and n were calculated by comparing the 
resulting data of fraction bound – determined from the protein bands of the ApoA-I in the nanoparticle-protein 
pellet – with the fraction bound calculated from inserting the various ApoA-I concentrations from the plasma 
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dilutions into the model binding curve (Eqn. (2.8)) and minimizing the sum of squares error. Results of the binding 
model predicted values and the experimental data are shown in Figure 2.1 – 2.3.  
Our results show that ApoA-I still has significant binding affinity for the polystyrene nanoparticles even in 
the presence of other competing plasma proteins; Kd-PSCOOH 1.1 µM, Kd-PSNH2 1.9 µM and Kd-PS 3.1 µM. In addition, 
the number of ApoA-I particles on nanoparticle surfaces was higher for the PS (n = 92) and PS-NH2 (n = 100) 
nanoparticles when compared with the PS-COOH (n = 58) nanoparticles pointing to potential surface chemistry 
effects on protein adsorption. To further elucidate the differences in binding, nanoparticle concentrations were 
increased while keeping plasma and hHDL concentrations constant. It is evident from Figure 2.4 that the depletion 
of ApoA-I in mouse plasma is hindered as PSNH2 nanoparticle concentrations are increased, but this effect is not 
noticeable for nanoparticles incubated with hHDL. It is possible that structural changes of ApoA-I and/or surface 
displacements by other proteins may have played a role in inhibiting ApoAI binding to PS-NH2 nanoparticles in 






















Researchers have demonstrated that PS-NH2 nanoparticles disturb the secondary structure of ApoA-I 
upon binding and this becomes even more pronounced at higher nanoparticle concentrations.14 Our investigations 
using circular dichroism (CD) confirmed their results after we incubated mHDL purified from whole plasma with 
PS-NH2 nanoparticles (Appendix A.5). Another possibility for the observed differences in the depletion of ApoA-I 
in mouse plasma by PS-NH2 nanoparticles could be because of the presence of nanoparticle-bound proteins in 
the supernatant. However, our studies using UV-VIS to examine the absorbance profile of both control and test 
samples after ultracentrifugation illustrate that this is clearly not the case (Appendix A.6) and that all particles are 
pelleted at the high g-forces. Restricted depletion of ApoA-I was therefore attributed to conformational changes of 
lipoproteins from binding to PS-NH2 nanoparticles and the possible competition from other plasma proteins 










2.4.2  mHDL Purification by Anion Exchange Chromatography 
 
In anion exchange chromatography, negatively charged molecules are attracted to the positively charged 
column (Source 15Q). This method utilized the characteristic that the relationship between the net surface charge 
experienced by a protein and the pH is unique to each individual protein. ApoA-I, the primary constituent of HDLs, 
should bind the positively charged column at the underlying pH of the buffer since it is greater than its isoelectric 
point (pI 5.3 – 5.823-24). Bound proteins were eluted when salt ions of NaCl competed for a spot on the charged 
surface of the column. As we increased the salt concentration, it promoted the elution of one or more distinct 
proteins (Appendix A.7). Proteins having a lower net charge or weaker interaction were eluted first while those 
having a higher net charge or interaction with the column were eluted in later fractions. Albumin, a common 
contaminant found in the purification of HDLs from plasma was mainly eluted at earlier elution fraction (Appendix 
A.7) steps while HDL fractions were eluted at higher salt gradients since their ionic strength was greater at the 
prevailing pH. After the %elution buffer and fraction numbers were established, we considered reducing the 
%elution gradient at the fraction numbers coinciding with the elution of HDLs (Figure 2.5 – 2.6).  
The initial salt gradient scheme employed 75% of elution buffer at the 85th fraction; this was changed to 
70% but the gradient of %elution buffer remained the same, about 0.053% elution buffer for every 1 ml fraction. 
The change in the %elution buffer allowed us to obtain more fractions of HDLs (Figure 2.7); however, the salt 
gradient scheme could be optimized further for the acquisition of better resolved fractions. Figure 2.8 shows the 
HDL pooled fractions from the purification procedures. As a result of the attained protein gel profiles, we opted not 







Figure 2.5  Elution of mHDLs and other Plasma Proteins at the Initial Salt Gradient Scheme. Left Panel: a-n, 





Figure 2.6  Chromatograms of the Purification of Lipoproteins from Mouse Plasma. Left Panel: Initial Salt Gradient 
Scheme. Right Panel: Final Salt Gradient Scheme. Linear gradient additions of elution buffer initiates after initial 








Figure 2.7  Elution of mHDLs and other Plasma Proteins from the Final Salt Gradient Scheme. Left Panel: a-n, 





Figure 2.8  Peaked Pooled Fraction of mHDLs from Anion Exchange Chromatography. Left Panel: mHDL Profiles 
in a 10-well Gel from Using the Initial Salt Gradient Scheme; a- fraction 87 - 88 and 91 – 94; b- 87 - 90. Right 
Panel: mHDL Profiles in a 15-well Gel from Using the Final Salt Gradient Scheme; a, 88 – 89; b, 90 – 93; c, 94 – 







2.4.3  Measurement of HDL Binding Parameters by ITC 
 
ITC is a commonly used technique to study the adsorption and thermodynamic parameters from the 
binding of biomolecules and ligands in solution. Since the experiments are carried out in situ, it enables us to 
directly obtain binding parameters for nanoparticle-protein interactions in solution and also to determine 
associations that may be favorable. Titrations were analyzed for the twenty-seven 10 µl injections of HDLs into 
nanoparticle solution in the cell, and the generated adsorption isotherms and heat changes from titrations are 
shown in Figure 2.9 – 2.10. All binding isotherms were fitted according to an independent binding model 
(Appendix A.1).19 
Examining the adsorption isotherms provides a quick way of gaining insight into the nature of binding 
between the HDLs and polystyrene nanoparticles. We can see from the steepness of the adsorption isotherms that 
the hHDLs have a higher binding affinity for PS and PS-COOH nanoparticles when compared with the mHDLs. 
However, it is difficult to make any inferences by visual inspection of the adsorption isotherms corresponding to 
PS-NH2 and HDL titrations except that mHDLs have a higher affinity to PS-NH2 than PS and PS-COOH. Table 2.1 
provides a summary of the values obtained from fitting the data according to the independent site binding model. 
Stoichiometry and binding affinity values from protein gel electrophoresis measurements are also included for 
reference.  
The results from the ITC experiment suggest that roughly 30 to 40 proteins constitute the corona proteins 
from the interaction of polystyrene nanoparticles with mHDLs. These values are in good agreement with the study 
performed with gel electrophoresis where the stoichiometry of binding of ApoA-I for PS, PS-COOH and PS-NH2 
nanoparticles are 92, 58 and 100 respectively. If HDLs are assumed to have around 3 – 4 ApoA-I molecules,25 





Figure 2.9  ITC Data from Titrating hHDL into Polystyrene Nanoparticles. (A) hHDL + PS. (B) hHDL + PS-COOH. 
(C) hHDL + PS-NH2. The top panels represent the raw data from titrations after referenced baseline correction. The 





Figure 2.10  ITC Data from Titrating mHDL into Polystyrene Nanoparticles. (A) mHDL + PS. (B) mHDL + PS-
COOH. (C) mHDL + PS-NH2. The top panels represent the raw data from titrations after referenced baseline 




Table 2.1  Adsorption Parameters Obtained from ITC and Protein Gel Electrophoresis 
 
Protein Nanoparticle n Ka (µM-1) Kd (µM) ΔH (kcal/mol) ΔS (cal/mol K) 
mHDL PS 30 ± 4.99 2.50 ± 0.511 0.4 -596.2 ± 12.51 -1970 
 PS-COOH 36.5 ± 8.91 1.11 ± 0.227 0.9 -1036 ± 318.2 -3450 
 PS-NH2 30 ± 0.678 39.5 ± 6.65 0.025 -711.3 ± 21.53 -2350 
hHDL PS 49 ± 1.44 11.1 ± 1.57 0.09 -450.8 ± 17.61 -1480 
 PS-COOH 34.2 ± 1.72 5.44 ± 0.596 0.184 -666.1 ± 42.06 -2200 




PS 92 0.32 3.1 - - 
PS-COOH 58 0.91 1.1 - - 
PS-NH2 100 0.53 1.9 - - 
*ApoA-I from whole mouse plasma. Experiments were carried out at 4 Celsius 
 
 
and PS-NH2 nanoparticles respectively. It should be remembered that the experimental conditions for both 
systems are different, and that could account for the differences observed in the binding of lipoproteins to the 
nanoparticles.  
 Stoichiometry values for hHDLs are slightly dissimilar from mHDLs and this is expected since the molar 
mass and HDL species are different. The molar mass as estimated by gel filtration chromatography was 140.8 kDa 
and 276.5 kDa for hHDLs and mHDLs respectively (Appendix A.8). It is expected that a higher molecular weight 
(MW) protein occupy less area on a nanoparticle surface given its size and the available area for binding. Binding 
affinities for the hHDL group revealed that the Kd values for PS-COOH and PS-NH2 were comparable and that the 
highest affinity was for PS. However, mHDLs displayed a different trend with mHDLs binding to PS-NH2 
possessing the highest affinity (PS-COOH < PS < PS-NH2).  
Conformational changes of the mHDLs may have played a role in the high values observed for binding to 
PS-NH2. Recently, Müller and coworkers employed ITC to study the binding of lipoproteins to PS nanoparticles 
and from results of their investigations they indicated that lipoproteins that first come into contact with PS 
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nanoparticles disintegrate and promote the complete saturation of the nanoparticle surface by lipids before 
additional lipoproteins bind to form the biomolecular corona.26 Therefore, it is seems probable that conformational 
changes in the mHDLs could have fostered the increased binding affinity for PS-NH2. Our CD data (Appendix A.5) 
and those of other researchers14 showing the loss in secondary structure of lipoproteins upon interaction with 
PSNH2 nanoparticles lend credence to this point, suggesting that this could be the case. It is possible that specific 
conformational states allow for the undocking of the lipid component of HDLs which facilitates disintegration, lipid 
binding to the nanoparticles and ultimately the binding of lipoprotein complexes.  
It should be noted, however, that a higher conformational change does not necessitate tighter binding, as 
has been recognized in other studies.27-28 In our study, hHDLs binding to PS-NH2 had the lowest binding affinity 
but its entropy was highest for all three nanoparticle types while hHDLs binding to PS had the highest binding 
affinity, but its entropy was lower. Research by Kono and coworkers suggest that ApoA-I could have different 
conformations (open or closed conformation anchored by the C-terminal domain) at the surface of a lipid particle 
depending on the ApoA-I concentration and cholesterol content on the particle.29 From their investigations, they 
proposed a mechanism whereby high cholesterol content (and low ApoA-I surface concentration) on the lipid 
particle promotes an open conformation while low cholesterol content (and high ApoA-I surface concentration) 
promotes the closed conformational state. Consequently, it appears plausible that there is an interplay between 
specific conformational states on lipoprotein molecules that enhances lipid release and binding to nanoparticles. 
 
2.4.4  Effect of Lipoprotein Binding and SCARBI Receptors on Nanoparticle Biodistribution 
 
 With Sarah Kauffman, we bred mice homozygous null for SCARBI. Mice were genotyped using PCR 
(Appendix A.9). Following intravenous injections with clodronate liposomes, it is expected that hepatic and splenic 
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macrophages be eliminated within 24 hours after administration of the recommended 0.01ml/g dose.30-31 
Macrophage depletion in the liver and spleen helped to decouple the effects of macrophage activity in these 
organs on nanoparticle uptake. We see from Figure 2.11 – 2.12 that after macrophage depletion, the uptake of PS-
COOH nanoparticles in the livers of male SCARBI-/- mice was significantly reduced. Interestingly, there was no 
significant change in the spleen. The lungs were considerably affected by the injection of clodronate liposomes as 
is evident in the significantly reduced uptake in male SCARBI-/- mice. In the rest of the investigated organs, we do 
not see any significant changes in nanoparticle uptake after macrophage depletion. Male mice that were injected 
with control liposomes saw only a significantly reduced uptake in the spleen of SCARBI-/-. Injected dye seemed to 
follow similar trends in uptake for males injected with clodronate and control liposomes, with exceptions in the 
lungs and kidneys in the clodronate liposome group and white adipose tissue (WAT) in the control group. 
In female mice, there appeared to be a reversal in the uptake of nanoparticles in the clodronate liposome-
treated group. The liver, spleen, heart and kidneys all showed a significantly increased uptake of nanoparticles in 
SCARBI-/- mice (Figure 2.13 – 2.14). This is intriguing because it was initially assumed that lipoproteins would 
bind nanoparticles and deliver them to SCARBI receptors in various organs. One possible reason for this 
difference could be size of the organs. SCARBI-/- mice of both male and female genders have been shown to 
have a tendency of exhibiting splenomegaly;32-33 therefore, the overall uptake per organ should be diminished and 
thus does not explain the significant differences observed in the spleen of female mice that were injected with 
clodronate liposomes. The splenomegaly effect in SCARBI-/- mice however brings up the question of organ size 
dissimilarities between SCARBI-/- and SCARB+/+ mice. 
 An inspection of the weights of the different organs (Figure 2.15 – 2.16) revealed that there were some 





Figure 2.11  Fluorescence Intensity of Organs of Male SCARBI Ex Vivo After Macrophage Depletion with 
Clodronate Liposomes. PSCOOH+dye values are means ± SD (n = 5) except SCARB -/- (n = 3), dye (n = 1), pbs 
(n = 1). + p < 0.05, ++ p < 0.01 as determined by t-test (an F-test for equal and unequal variances was done and 





Figure 2.12  Fluorescence Intensity of Organs of Male SCARBI Ex Vivo After Injections with Control Liposomes. 
PSCOOH+dye values are means ± SD (n = 5), dye (n = 1), pbs (n = 1) except SCARB -/- (n =2). ++ p < 0.01 as 






Figure 2.13  Fluorescence Intensity of Organs of Female SCARBI Ex Vivo After Macrophage Depletion with 
Clodronate Liposomes. PSCOOH+dye values are means ± SD (n = 5), dye (n = 1), pbs (n = 1). ++ p < 0.01, +++ 
p < 0.001 as determined by t-test (an F-test for equal and unequal variances was done and the corresponding t-





Figure 2.14  Fluorescence Intensity of Organs of Female SCARBI Ex Vivo After Injections with Control Liposomes. 
PSCOOH+dye values are means ± SD (n = 5), dye (n = 1), pbs (n = 1). + p < 0.05 as determined by t-test (an F-






Figure 2.15  SCARBI Female Organ Weights. n = 5. + p < 0.05 as determined by t-test (an F-test for equal and 





Figure 2.16  SCARBI Male Organ Weights. n = 5, but wclod SCARBI-/- n = 3. + p < 0.05, +++ p < 0.001 as 
determined by t-test (F-test for equal and unequal variances was done and the corresponding t-test was applied). 
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liposome group. Hence, the size of the spleen and WAT could possibly explain the decreased and increased 
uptake of nanoparticles respectively by female SCARBI-/- mice for the control liposome group. There were not any 
significant differences in all the other pairs for both the clodronate and control liposome group. Consequently, the 
increased nanoparticle uptake in the liver, spleen, heart and kidneys of the clodronate liposome-treated group of 
female mice was not influenced by organ size. No particular trends were observed within either the clodronate 
liposome-treated or control liposome group after the injection of dye. Nonetheless, we do see some trends in the 
biodistribution of the dye across the two groups with the exception of WAT; also pointing to the importance of 
SCARBI receptors in nanoparticle biodistribution.  
For male mice, the differences in liver weights may potentially explain the decreased uptake; but it does 
not explain the drastically increased uptake by the lungs since there were no organ size differences. The SCARBI 
receptors were the likely cause for the increased uptake, and our results also suggests a different mode of 
macrophage depletion in the lungs by intravenously injected clodronate liposomes. Clodronate liposome 
mechanism of action is such that after macrophage engulfment and fusion with lysosome, the phospholipid 
bilayers of clodronate liposomes are broken down by lysosomal enzymes (phospholipases) which then releases 
the clodronate drug.34 The clodronate drug by itself cannot cross the phospholipid bilayers of the liposomes so 
that more drug is released with an increase in the disruption of concentric phospholipid bilayers.35 Since free 
clodronate cannot cross the phospholipid bilayer, it will not easily pass the phospholipid bilayers of cell 
membranes. Moreover, the half-life of free clodronate is extremely short (order of minutes) and will only spend a 
short time in circulation if released from dead macrophages.36 Therefore, there has to be another mechanism by 
which clodronate liposomes deplete macrophages in the lungs since free clodronate are removed from circulation 
rapidly and it would not readily pass through the interstitial blood-gas barrier.  
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Koay and coworkers demonstrated that intravenous injection of 200 µl (5 mg/ml) clodronate liposomes in 
C57BL/6 mice depleted 66% of alveolar macrophages in the bronchial alveolar lavage fluid after 48 hours.37 The 
exact mechanism for this depletion is unclear. Considering the depletion of bone marrow macrophages by 
clodronate liposomes,38 perhaps, the recruitment of bone marrow macrophages enriches alveolar macrophages in 
lungs since macrophage populations in the lungs can arise from bone marrow-derived blood monocytes.39-40 It 
may then be possible that a recruitment of pulmonary intravascular monocytes/macrophages (e.g. due to 
nanoparticle burden) are either indirectly or directly affected by bone marrow macrophage depletion in the SCARBI 
mice.41  
 Disparities in the mode of nanoparticle uptake between male and female mice may be a consequence of 
distinct lipid and lipoprotein metabolism in the two genders. Our findings from measurements of plasma HDL and 
LDL/VLDL cholesterol content in mice treated with clodronate liposomes and control liposomes suggests this 
phenomenon. Plasma HDL cholesterol content was lower in female SCARBI+/+ mice in the clodronate liposome-
treated group while the opposite was observed for male SCARBI+/+ mice (Figure 2.17). This shows the potential 
for macrophage cholesterol homeostasis to be differentially affected in the different genders. The decrease in 
plasma HDL cholesterol displayed by female SCARBI+/+ mice could signify a more selective and involved SCARBI 
receptor-mediated control of cholesterol metabolism, while the increase in plasma HDL cholesterol seen in male 
SCARBI+/+ is not surprising since macrophages as a whole play a role in the regulation of cholesterol uptake. It is 
worth noting that the absence of the SCARBI receptor increased plasma LDL/VLDL cholesterol concentrations. 
This is predictable because SCARBI can function as a multiligand receptor for HDLs, LDLs and VLDLs.42 Research 






Figure 2.17  Plasma HDL and LDL/VLDL Concentration in Male and Female Mice Treated With Clodronate and 
Control Liposomes. For SCARBI+/+, n = 3 for all except females treated with clodronate liposomes n = 4. For 
SCARBI-/-, n = 3, 4, 4 and 5 for males treated with clodronate liposomes, control liposomes; and females with 
clodronate liposomes, control liposomes respectively. + p < 0.05 and ++ p < 0.01 as determined by t-test (an F-




















a high fat diet, and these VLDL particles were rich in apoE.43 Rigotti and coworkers also found similar apoE-rich 
VLDLs in the plasma cholesterol of SCARBI-/- mice that were fed a regular diet.44  
 In the HDL SCARBI-/- group, it is unclear why no significant changes in plasma HDL cholesterol were 
detected in both female and male mice; it may be possible that the absence of macrophages and SCARBI 
receptors is compensated for by other SCARBI-independent pathways or the net flux of plasma HDL cholesterol 
from macrophage uptake and SCARBI-independent pathways. However, differences in plasma HDL cholesterol 
levels in SCARBI+/+ mice treated with clodronate liposomes does suggest different mechanisms for lipid and 
lipoprotein metabolism between male and female mice. A study by Brodeur and coworkers provide more 
validation for genetic differences in lipid and lipoprotein metabolism.45 Their core findings showed that the selective 
uptake of LDL cholesteryl esters in the livers of male and female mice is carried out by both an SCARBI-dependent 
and independent pathway, with females displaying much higher SCARBI-independent activity. Others have also 
noted gender-related differences in cholesterol uptake46-48 and drug metabolism,49-50 and these would have 
significant implications in nanoparticle drug delivery. 
 
2.5  Conclusion 
 
 Lipoproteins bind nanoparticles, but their affinity depends on the composition of the nanomaterial and the 
conformational state of lipoproteins during binding. The release of lipids from lipoproteins could also direct 
binding kinetics and the flux of lipoprotein complexes after lipoprotein fragmentation from contact with the 
nanoparticle surface. Due to the functions of lipoproteins in cholesterol metabolism, intravenously injected 
nanoparticles could bind lipoproteins and be diverted away from intended targets to lipoprotein receptors in the 
body. Gender differences could also affect nanoparticle drug delivery because of the selective uptake of cholesteryl 
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esters by scavenger receptors. Overall, lipoproteins and lipid metabolism have been shown to be important 
contributors to the biodistribution of nanoparticles. These findings should make us become more aware of the 
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A.1  Isothermal Titration Calorimetry: Single Set of Independent Sites Binding Model 
 
In this model, we assume that the nanoparticle (N) contains identical and independent binding sites 
for the ligand (L), and that the ligand binds without any cooperative effects. The reaction under 
consideration can then be written as,  
[𝑁] + [𝐿] ⇌ [𝑁𝐿]                                                                                                                         (𝐴1) 
[𝑁𝑇] = [𝑁𝐿] + [𝑁]                                                                                                                      (𝐴2) 
[𝐿𝑇] = [𝑁𝐿] + [𝐿]                                                                                                                        (𝐴3) 
where [N] and [L] are the concentrations of free nanoparticle and ligand respectively. [NT] and [LT] are 
the total concentrations of nanoparticle and ligand respectively while [NL] is the nanoparticle-ligand 
complex concentration. 
The equilibrium association constant of the interaction of nanoparticle with ligand can be expressed 
as, 





(1 −  𝛩)[𝐿]
                                                                                                    (𝐴4) 
where Θ is the fractional saturation, that is, the fraction occupancy of ligand binding sites on a 
nanoparticle saturated, and by conservation of mass,  
[𝐿𝑇] = [𝐿] + 𝑛𝛩[𝑁𝑇]                                                                                                                   (𝐴5) 
where n is the number of binding sites and combining equations (4) and (5) gives a quadratic 
equation,  






) +  
[𝐿𝑇]
𝑛[𝑁𝑇]
=  0                                                                (𝐴6) 
Solving the quadratic equation gives the root of Θ, 
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𝛩 =  
1
2

















 )              (𝐴7) 
The total heat of reaction Q in the cell is then given by, 
𝑄 = 𝑛𝛩[𝑁𝑇]𝑉0∆𝐻                                                                                                                        (𝐴8) 
where V0 is the cell volume and ΔH is the molar heat of ligand binding 
Taking into consideration the injection volume ΔVi for injection i, a correction is needed to account for 
this displaced volume. The displaced volume contributes about 50% as much heat as an equivalent 
material in the working volume Vo, such that the heat released from the ith injection is, 




𝑄𝑖 +  𝑄𝑖−1
2
) −  𝑄𝑖−1 = 𝑄𝑖 (1 +
∆𝑉𝑖
𝑉0
) − 𝑄𝑖−1 (1 −  
∆𝑉𝑖
𝑉0
)                     (𝐴9) 
 
The procedure of fitting the experimental data involves making initial guesses to n, Ka and ΔH. Using 
these initial guesses, the heat ΔQi for each injection is calculated and compared to the measured heat 
values for the corresponding experimental injection. Optimizations to the parameters, n, Ka and ΔH, 
are done with Levenberg-Marquardt methods and further iterations are carried out until no significant 
improvement is observed and the fit parameters converge.  
To calculate change in entropy (ΔS), the reaction isotherm equation (A10) and Gibbs-Helmholtz (A11) are 
combined to solve for ΔS (A12), 
 
∆𝐺 =  −𝑅𝑇 ∙ 𝑙𝑛𝐾𝑎                                                                                                                     (𝐴10) 
 
∆𝐺 =  ∆𝐻 − 𝑇 ∙ ∆𝑆                                                                                                                    (𝐴11) 
 
∆𝑆 = 𝑅 ∙ 𝑙𝑛𝐾𝑎 +  
∆𝐻
𝑇
                                                                                                                (𝐴12) 
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where ΔG is the Gibbs free energy, T is the temperature and R is the universal gas constant. ΔS can then be 
calculated for known values of Ka and ΔH 
 
A.2  Protein Gel Calibration  
 
Several known concentrations of BSA were made and used to calibrate the in-gel standard (1/20X mouse plasma). 
Any protein band on the 1/20X band profile can be used as a relative standard and all major protein bands on the 




Figure A.2-1  Protein Gel Calibration of 1/20X Plasma with BSA in 10-well Gels. (A) Lane 2- 1/20X plasma, lane 
3- 0.175 µg, lane 4- 0.25 µg, lane 5- 0.5 µg, lane 6- 1 µg, lane 7- 2 µg, lane 8- 4 µg, lane 9- 8 µg. (B) Lane 2- 







Figure A.2-2  Protein Gel Calibration of 1/20X Plasma with BSA in 15-well Gels. (A) and (B) Lane 1- 0.05 µg, lane 
2- 1/20X plasma, lane 3- 0.125 µg, lane 4- 0.15 µg, lane 5- 0.175 µg, lane 6- 0.25 µg, lane 7- 0.5 µg, lane 9- 1 
µg, lane 10- 0.1 µg, lane 11- 2 µg, lane 12- 0.075 µg, lane 13- 8 µg, lane 15- 4 µg.  
 
 





Figure A.3-1  Protein Gels of PSCOOH Binding to 1/5X – 1/2X plasma. (A) 2- 1/20X standard, 4- 1/3X plasma, 6- 
1/3X plasma + PSCOOH, 8- 1/2X plasma, 10- 1/2X + PSCOOH, 12- 1/5X plasma, 14- 1/5X plasma + PSCOOH. 







Figure A.3-2  Protein Gels of PSCOOH Binding to 100X – 1/20X plasma. (A) 2- 1/20X standard, 3- 1/50X, 4- 
1/50X + PSCOOH, 6- 1/20X  + PSCOOH, 7- 1/20X, 8- 1/100X, 9- 1/100X + PSCOOH. Lane 3 – 9, supernatant. 





Figure A.3-3  Protein Gels of PSCOOH Binding to 100X – 1/60X plasma. (A) 2- 1/20X standard, 3- 1/100X + 
PSCOOH, 4- 1/100X, 5- 1/70X, 6- 1/70X + PSCOOH, 8- 1/60X, 9- 1/60X + PSCOOH. Lane 3 – 9, supernatant. 
(B) 2- 1/20X standard, 3- 1/100X, 4- 1/100X + PSCOOH, 6- 1/70X + PSCOOH, 7- 1/70X, 8- 1/60X, 9- 1/60X + 



























































Figure A.6-1  Absorbance Spectra Showing Complete Nanoparticle Pelletization After Ultracentrifugation. Left 
Panel: Depicting absorbance spectra without ultracentrifugation. Right Panel: Depicting the supernatant absorbance 














Figure A.7-1  Protein Gels Depicting the Elution of One or More Distinct Plasma Proteins Prior to Changing the 
Salt Gradient Scheme. Left Panel: a-b, fraction 44 – 46; d – m, fraction 51-60. Right Panel: a-m, fraction 61-74. 
 
 





Figure A.8-1  Calibration Curve for Estimating the Molecular Weights of mHDL and hHDL 
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Figure A.9-1 SCARBItm1kri Genotyping with PCR. Wild-type represent one 262 bp band, mutant represents one 140 
bp band, while heterozygous represents both 140 bp and 262 bp bands. 
 
 










Figure A.10-2  Organ weight differences between male and female mice injected with either clodronate liposomes 
or control liposomes. + p < 0.05, ++ p < 0.01 as determined by the t-test (an F-test for equal and unequal 
variances was done and the corresponding t-test was applied). n.s. p. denotes no significant difference between all 










The Localization of Soft Nanoparticles to the Liver and Spleen is Significantly 































3.1  Abstract 
 
Due to the prevalence of overweight and obese individuals in the United States being 70% and 30% 
respectively among adults, it is likely that many prospective patients that will be administered nanotherapies will 
have additional metabolic complications. Yet, studies on the distribution of nanoparticles and their efficacy occur 
mostly in lean rodents. Here, we determined the biodistribution of model nanoparticles – filomicelles – as a 
function of mouse diet and weight utilizing three strains: C57BL/6J, KK-Ay, and ob/ob. C57BL/6J mice are largely 
resistant to significant weight gain, but KK-Ay and ob/ob mice become obese on a high-fat diet. I found that there 
was a significant drop in the accumulation of nanoparticles in the livers and spleens of KK-Ay and ob/ob mice as 
their weights increased. Interestingly, almost no nanoparticles localized to the white adipose tissue (WAT) of any of 
the mice. These results have significant implications for patients with altered metabolic states. 
 
3.2  Introduction 
 
The biodistribution of a nanoparticle in model mammals such as mice provides clues as to the future 
promise of nanoparticles in treating human diseases. However, the vast majority of experiments that determine the 
biodistribution of nanoparticles take place after administration to metabolically healthy rodents.1 This methodology 
has provided a wealth of insight into mammalian response to nanoparticles. However, the vast majority of patients 
that will potentially be administered nanoparticles in the clinic will be overweight to obese and have widely varying 
metabolic conditions. These imbalances could greatly affect nanoparticle biodistribution and future efficacy.2-3  
Here, I determined the biodistribution of cylindrical poly-ethylene-oxide–block-poly-butadiene PEO-b-
PBD filomicelles in three mouse strains: C57BL/6J, KK-Ay, and ob/ob. C57BL/6J (wild-type) mice are not an ideal 
model for diet-induced obesity, thus the need for the KK-Ay and ob/ob strains. However, I was able to maintain the 
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weights of the KK-Ay and ob/ob mice at lean C57BL/6J levels (~25-30 g) by limiting their diets to 4 grams of low-
fat feed (LFD) per mouse per day. I determined that nanoparticle localization to the liver and the spleen decreased 
by up to factors of ~4 and ~10, respectively, from the lean (~30 grams) to the heaviest (~55-60 g) KK-Ay and 
ob/ob mice. Nanoparticle signal in WAT was just above background, indicating that it is not a major sink. This also 
indicates that any adipose tissue macrophages (ATMs) had a limited role in nanoparticle clearance. My results 
show that mammalian diet and weight play crucial roles in the biodistribution of model nanoparticles. 
 
3.3  Materials and Methods 
 
3.3.1  Synthesis of Diblock Copolymers for Filomicelles 
 
Poly-ethylene-oxide-block-poly-butadiene (PEO-b-PBD) copolymers were synthesized following the techniques of 
Hillmyer and Bates.4 s-BuLi (1.4 M in cyclohexane; Sigma-Aldrich #195596) and n-BuLi (2.0 M in cyclohexane; 
Sigma-Aldrich #302120) were diluted with hexane under vacuum. Potassium naphthalenide (K-Naph) was 
prepared with naphthalene and potassium in THF. 1,3-butadiene (BD; Sigma-Aldrich #695580) was distilled two 
times over n-BuLi sequentially and diluted with two-fold excess of THF. Ethylene oxide (EO; Sigma-Aldrich 
#387614) was distilled over n-BuLi two times sequentially and distilled again to each ampoule. Tetrahydrofuran 
(THF; Fisher #T397-1) was distilled under N2 after refluxing with sodium for 5 h and over K-Naph under vacuum. 
All initiators and monomers were stored at -30 °C in ampoules equipped with break-seals. 
The polymer number-average molecular weight and polydispersity index were determined using size exclusion 
chromatography (SEC) equipped with a Knauer’s K-501 HPLC pump, K-2301 RI detector, K-2501 UV detector, 
and with a set of two columns; Polymer Standards Services, SDV-gel, 60 cm length (5 mm) 100 Å and a linear 
102–106 Å. THF with toluene as a solvent flow marker, was used as an eluent at a flow rate of 1.0 mL min-1, and 
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the SEC was calibrated using polystyrene (PS) standards obtained from Pressure Chemicals (Pittsburgh, USA). 
The 1H-NMR spectra (JEOL JNMLA300WB) were measured using CDCl3 as the solvent. 
The anionic polymerization of butadiene (BD) was performed under high-vacuum conditions (10-6 Torr) in sealed 
glass apparatus equipped with break-seals. The polymerization reactors was washed with the initiator solutions of 
K-Naph in THF after sealed off from the vacuum line. The initiator solution of s-BuLi in hexane (1.22 mmol, 
0.61M) was transferred into the reactor and stabilized at -60 °C for 5 min. The monomer solution of butadiene in 
THF (3.2g, 59.2 mmol, 1.2 M) was introduced quickly into the initiator solution at -60 °C. The solution turned 
deep yellow, which indicated successful initiation. The polymerization was carried out at -60 °C and the color of 
polymeric solution became light orange. After 6 h, ethylene oxide (1.0 ml, 20 mmol) was added at -60 °C and the 
reaction became colorless rapidly. The end-capping reaction of living polybutadiene with EO was carried out with 
stirring at room temperature overnight. The reaction was terminated with acidic methanol. The hydroxyl-end 
capping polybutadiene (PBD-OH) was precipitated in a large amount of methanol and dried in vacuum oven for 3 
days. The polymer (3.23 g) was obtained with 99.5 % of yield and characterized using 1H-NMR and SEC. 
Molecular weight from SEC is 2,730 g/mol (polydispersity index: 1.06). 1H-NMR spectra (CDCl3, 500 MHz),  
(ppm): 5.6-5.2 (CH2-CH=CH-CH2- and CH2=CH-CH-), 5.0-4.8 (CH2=CH-CH-), 3.6 (-CH2-OH), 2.3-1.8 (CH2-
CH=CH-CH2-and CH2=CH-CH-), 1.5-1.0 (CH2=CH-CH-CH2-), 0.85(-CH3 from initiator).  
The viscous polymer of PBD-OH (3.0 g, 55.5 mmol) was dried under reduced pressure for 3 days and the 
solution of PBD-OH in THF (1.0 M) was prepared by distilling THF over K-Naph under vacuum. The solution of 
PBD-OH was titrated by adding the deep green solution of potassium naphthalenide in THF drop by drop until a 
light green solution persisted for 1 h. The monomer of EO (3.4 ml, 68.2 mmol) was introduced to the solution. 
The polymerization in THF was heated to 60 °C with stirring for 5 days. The acidic methanol was added to the 
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solution of block copolymer PBD-b-PEO. The THF and methanol was evaporated completely. PBD-b-PEO was 
redissolved in chloroform and extracted with deionized water three times. After evaporation of chloroform, the 
block copolymer of PBD-b-PEO was dried by heating to 40 °C for 2 days in vacuum drying oven. The pure block 
copolymer of PBD-b-PEO (5.94 g) was obtained with 99 % of yield and characterized using 1H-NMR and SEC. 
Molecular weight from SEC is 5,380 g/mol (polydispersity index: 1.09). 1H-NMR spectra (CDCl3, 500 MHz),  
(ppm): 5.6-5.2 (CH2-CH=CH-CH2- and CH2=CH-CH-), 4.9-4.7 (m, CH2=CH-CH-), 3.7-3.4(-O-CH2-CH2-O-), 2.2-
1.8 (CH2-CH=CH-CH2-and CH2=CH-CH-), 1.4-0.9 (CH2=CH-CH-CH2-), 0.6(-CH3 from initiator).  
 
3.3.2  Nanoparticle Preparation 
 
Filomicelles were formed from PEO-b-PBD copolymers using film rehydration with phosphate buffered saline 
(PBS) as the aqueous buffer as described previously.5 Prior to injection, copolymers that did not form filomicelles 
were pelleted at 25°C for 15 minutes at 15,000 x g. The upper phase containing the dispersed filomicelles was 
reserved for injection, with the amount of copolymer in the pellet being minimal. High-aspect-ratio nanoparticles 
such as filomicelles should not in general be forced through filters as many of the nanoparticles will be lost.6 All 
nanoparticles were loaded with near-infrared (NIR) dye for imaging Life Technologies, #D-12731.5 The dye 
partitions into the hydrophobic interiors of the nanoparticles and does not leak in vivo.5 
 
3.3.3  Mice 
 
All mouse experiments were approved by the University of Tennessee’s Institutional Animal Care and Use 
Committee. I used C57BL/6J (Jackson Laboratories; #000664), KK-Ay (Jackson Laboratories; #002468), and 
ob/ob mice (Jackson Laboratories; #000632). I controlled their weights by the amount and duration that they were 
83 
 
on either low-fat (Research Diets, #D12450B) or high-fat diets (Research Diets, #D12492). All weights were 
recorded before both injection and 24 hours later before euthanization. No appreciable differences were observed. 
 
3.3.4  Imaging 
 
Mice were euthanized by cervical dislocation under isoflurane anesthesia and the organs and white adipose tissue 
were immediately harvested and imaged for NIR signal in the IVIS Lumina system 
 
3.4  Results and Discussion 
 
I wished to determine filomicelle biodistributions in mice whose weights were controlled by diet and 
genetics. I used C57BL/6J mice as a model system for wild-type mice. I used KK-Ay and ob/ob mice as two 
models of obesity. Heterozygote KK-Ay mice become obese after a few weeks on a high fat diet (HFD).7 This is due 
to fat cell hypertrophy potentially caused by a reduction in hypothalamic norepinephrine and dopamine.7 
Homozygous ob/ob mice lack leptin a hormone secreted by adipocytes that acts on hypothalamic neurons to 
regulate energy and glucose balance.8 The weights of the three strains of mice were controlled by diet, the duration 
of time on that diet, and ranged from ~25 to ~60 grams (Figure 3.1A). The leanest mice in each of the three strains 
had a restricted low-fat diet (LFD) of 4 grams/day per mouse. After each population of mice had reached the 
desired weight, three mice in each set were tail-vein injected with 100 µl of ~10 mg/ml filomicelles carrying NIR 
dye (filomicelles-NIR) in PBS.5 We also injected one additional mouse with the equivalent amount of NIR dye in 
PBS, and one additional mouse with PBS. 48 hours after injection the mice were humanely euthanized and the 
liver, spleen, lungs, kidneys, WAT, and heart were immediately harvested along with the blood, which was 
separated into cells and plasma. I subtracted the intensity of the organs exhumed from the mice that were injected 
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with PBS from the intensity of the organs exhumed from the mice that were injected with filomicelles-NIR. All 
organs were washed with cold PBS and were immediately imaged for NIR signal using the IVIS Lumina system. 
There was a significant drop in filomicelles-NIR signal across the three strains as a function of liver weight 
(Figure 3.1B,C). This was especially evident between KK-Ay and ob/ob mice that were on a restricted LFD diet (4 
grams/day) versus mice with the same genetic backgrounds that were on an unlimited HFD (Figure 3.1C). There 
was a similar trend in the filomicelles-NIR signal in the spleens in these same mice (Figure 3.2A,B). There was a 
striking difference in the localization of filomicelles-NIR to the liver and the spleen versus WAT across all of our 
mouse models. Although mice on a HFD can have significant amounts of WAT (Figure 3.2C), filomicelles-NIR do 
not localize there (Figure 3.2D,E). Only mice that are on a LFD have NIR signals in their WAT that are above the 
background signal (Figure 3.2D,E). There were no major differences in the nanoparticle-NIR signals in the lungs, 
heart, and kidneys among any of the mice (data not shown). 
The accumulation of nanoparticles in the liver and spleen decreased in obese versus lean mice and this 
may be due to the activity of macrophages. Macrophage populations are heterogeneous;9 M1 macrophages are 
classically activated as the result of the overproduction of proinflammatory cytokines whereas M2 macrophages 
express immunosuppressive factors that promote tissue remodeling and help resolve inflammation.10 However, 
recent work has shown that culturing macrophages in an environment of glucose, insulin, and palmitate - which 
emulates the metabolic condition - result in a unique phenotype called “metabolic activation”.11 This agrees with 
recent findings in the literature where it was shown that migrating macrophages buffer the rest of the body from 
neutral lipids / fatty acids released from WAT.12-13 It is possible that the exposure of macrophages to high levels of 
fatty acids inhibits their ability to engulf nanoparticles and foreign objects in general. This could also explain the 
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modest activity of Kupffer cells in enlarged livers and the reduction in filomicelle-NIR localization in the spleen in 
ob/ob mice if neutral lipids are also reaching those areas of the body in obese individuals. 
Nanoparticles accumulate in WAT as a function of WAT mass, which for obese individuals can account for 
a large fraction of their total weight: in the ob/ob mice, WAT weight was ~¼ of their total weight. However, based 
on the NIR intensity of the pixels in the WAT images of obese mice, this appears to be a passive and not an active 
effect. The targeting of nanoparticles to WAT for obesity treatments has been of recent interest,14-16 but a thorough 
study of nanoparticle distribution as a function of patient weight is – to our knowledge – lacking.  
 
3.5  Conclusion 
 
Here, I determined the biodistribution of soft near-infrared (NIR)-carrying filomicelles as a function of 
patient weight and metabolic state using diet-induced obese mice and mice homozygous null for leptin, an 
adipokine that regulates appetite.8 Filomicelles were chosen as model nanoparticles because of their PEG brush, 
long circulation times, and their effectiveness in targeting and shrinking tumor xenographs in mice.5, 17 With these 
properties, I propose that this system be considered as an effective baseline to quantify general nanoparticle 
biodistribution as a function of patient metabolic state. Chemical and physical modifications that model the 
properties of specialized nanoparticles of interest can be easily made.18  
To provide broad insight into the effects of diet and weight on nanoparticle biodistribution, I used four sets 
of mice ranging from lean (27 ± 1 g) to obese (60 ± 2 g). In lean mice, the liver, spleen, lungs, kidney, and heart 
showed NIR signals in decreasing order with the liver and spleen dominating as expected.17 Surprisingly, when the 
weight of the mice was increased through a HFD leading to significant WAT mass, the NIR signal increased in 
WAT as a linear function of its mass. Even in mice with moderate weights (20% heavier than lean mice), the signal 
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of the combined WAT was comparable to that of the spleen. In ob/ob mice, the combined NIR intensity of the 
WAT was more than twice that of the spleen. These results show that obesity can have a profound influence on the 
























Figure 3.1.  Biodistribution of filomicelles in mice as a function of diet, weight, and genetics. (A) Plot of the weights 
of mouse livers as a function of mouse weight at the time of injection of filomicelles carrying NIR dye (filomicelles-
NIR). Open symbols represent mice that were fed a low fat diet (LFD). Closed symbols represent mice that were 
fed a high fat diet (HFD). Mice that are represented by the open symbols in the box were restricted to 4 g/d of 
LFD. (B) Fluorescent images of livers from the mice that were injected with filomicelles-NIR. (C) Fluorescent 
intensity of the livers shown in (B). Each data point represents three livers. (D) Plot of the weights of mouse 







Figure 3.2  (A) Fluorescent images of spleens from the mice that were injected with filomicelles-NIR. (B) 
Fluorescent intensity of the spleens shown in (A). Each data point represents three spleens. (C) Plot of the weights 
of mouse WAT as a function of mouse weight at the time of injection of filomicelles-NIR. (D) Fluorescent images of 
the WAT from the mice that were injected with filomicelles-NIR. (E) Fluorescent intensity of the WAT shown in (D). 
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4.1  Abstract 
 
Our novel crossing of Eµ-myc and ob/ob, done with the help of Sarah Kauffman, provided useful for 
understanding some of the effects of diet-induced obesity on the proliferative nature of B-cell malignancies. We 
show here that diet has the capability of causing significant changes to lymph node and splenic architecture. High 
fat-diet consumption for prolonged periods was shown to cause lymphoid hyperplasia cholesterol granuloma and 
foamy macrophages in lymph nodes of ob/ob mice. When ob/ob mice were placed on a high-fat diet and 
administered paclitaxel, there was still an identification of marked follicular lymphoid hyperplasia in their spleens. 
This is particularly interesting since paclitaxel is generally known to reduce lymphocyte numbers. Male ob/OB x 
Eµ-myc that were fed a high-fat diet also had a worse diagnosis than their female counterparts that were fed a low-
fat diet. Altogether, our studies point to the potential of obesity status to influence B-cell lymphoma. 
 
4.2  Introduction 
 
Non-Hodgkin’s lymphoma (NHL) constitutes a heterogenous group of lymphoproliferative malignancies 
with approximately 85% arising from B-cell lymphocytes while the remainder are derived from T-cells and natural 
killer cells.1 These malignant lymphomas generally emerge from cancerous lymphocytes in the lymph nodes but 
can develop anywhere lymph tissues are found in the body.1 Based on histopathological features, the lymphomas 
can be broadly categorized as indolent or aggressive. Indolent lymphomas are usually incurable and tend to less 
responsive to each successive treatment of chemotherapy over the history of the disease.2 On the other hand, 
aggressive lymphomas are typically characterized by a rapid symptom onset and if the disease is left untreated, 
death could occur fairly quickly although most cases of aggressive lymphoma can be cured if chemotherapy is 
initiated in a timely manner.2 
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Treatment of NHL can often be complicated by the presence of underlying conditions3-5 and 
understanding the impact of such comorbidities on lymphoma therapy is important in determining potential 
preventive regimens and therapeutic strategies. Obesity, in particular, is one of such conditions that is highly 
prevalent in the United States and most of the Western world;6 therefore, it is possible that overweight and obese 
patients would often be encountered for lymphoma treatment. Although obesity is a well-known risk factor for 
developing NHL,7-8 there is scant knowledge about the impact of obesity on the aggressiveness or overall survival 
in lymphoma cases. Most studies in literature are non-experimental epidemiological studies and their results are 
conflicting.9-16 Some researchers found a positive association between overweight or obese patients and survival 
while others found a deleterious association or none at all. 
Body mass index (BMI) was used in these epidemiological studies as a measure of body fat and patients 
were stratified into various groups depending on their BMI. Since there were no quantifiable indicators for obesity-
related disease aggressiveness, overall survival was considered as an alternate measure for the impact of obesity 
in the NHL cases. In summary, diffuse large B-cell lymphoma (DLBCL) was the predominant aggressive NHL 
subtype examined and obesity-related impact on overall survival was inconclusive since these studies lacked a 
consistent objective grouping measure for body fat, and other influential factors such as established NHL treatment 
regimens or age, gender and people groups were not comparable across all studies. Although the non-
experimental epidemiological studies were inconclusive, the results do show that obesity is an important factor that 
needs to be considered in the treatment and survival of lymphoma patients. To this end, experimental studies (e.g. 




While there is limited experimental information on how obesity impacts NHL, a couple studies provide 
some insight as to the relevance of body fat in NHL cases. Huang and coworkers utilized C57BL6/J and 
peroxisome proliferator-activated receptor-α deficient (PPAR-α -/-) mice bearing B-cell tumors induced by 
Bcr/Abl-transformed B-cells to study the effect of tumor development on lipid mobilization and distribution.17 They 
found that it could be possible for the B-cell tumors to elicit lipid mobilization from white adipose tissue to the liver, 
with subsequent increased export of serum lipids in the form of very low density lipoprotein (VLDL)/low density 
lipoprotein (LDL) to further promote tumor growth. Results of their investigations also showed that fenofibrate, a 
lipid-lowering drug and PPAR-α agonist, altered hepatic lipid metabolism and suppressed tumor growth. In a 
different study by the same group, they used VLDL production-deficient mice, carboxylesterase 3/triacylglycerol 
hydrolase -/- (Ces3/Tgh -/-), to further elucidate the mechanism by which tumor progression was dependent on 
tumor-induced hyperlipidemia.18 They discovered that Ces3/Tgh -/- mice were resistant to tumor-induced hepatic 
LDL receptor (LDLR) downregulation and hyperlipidemia which resulted in significantly diminished growth of 
Bcr/Abl-transformed B-cell tumors.  
Other researchers’ works have also pointed to the potential for altered lipid metabolism to impact B-cell 
lymphoma growth,19-21 however, more studies need to be done to further assess the impact of body fat or obesity 
on B-cell lymphoma cases. In light of our current limited knowledge of B-cell lymphoma metabolism, we 
proposed to incorporate obesity and B-cell lymphoma in a single mouse model to better understand the effects of 






4.3  Materials and Methods 
 
All animal experiments were conducted using institutionally approved protocols by the Institutional Animal 
Care and Use Committee (IACUC) at the University of Tennessee, Knoxville. Veterinarians (MMF & KN) at the 
University of Tennessee, Knoxville were blinded for all submitted samples. 
 
4.3.1  Breeding and Injections 
 
Heterozygous obese (ob/OB; stock# 000632, JAX Laboratory, United States) female mice were bred with male 
mice that develop B-cell lymphomas (OB/OB B6.Cg-Tg(IghMyc)22Bri/J; stock# 00278, JAX Laboratory, United 
States). Mice with the desired genotypes were separated into two groups; one given a high-fat diet (D12492, 
Research Diets, Inc., United States) to induce obesity and another on a low-fat diet (D12450B, Research Diets, 
Inc., United States) to serve as a control. After confirmation of obese or B-cell lymphoma status, mice were 
intravenously administered either 100 µl 1X PBS or 5 mg/kg paclitaxel (PTX) drug five to six days before blood 
collection.  
 
4.3.2  PCR Screening for Mice Genotype – LepOb 
 
Mouse tail snips were performed, and genomic DNA extractions were carried out according to manufacturer’s 
protocol using DirectAmp tissue genomic DNA amplification kit (Denville Scientific, United States). The following 
stock primers were used as recommended by JAX Laboratory for Lepob: oIMR1151 common,5’-TGT CCA AGA 
TGG ACC AGA CTC-3’; and oIMR1152 common, 5’-ACT GGT CTG AGG CAG GGA GCA-3’. Stock primers were 
diluted to 100 pmoles/µl and a fresh primer mix was made by diluting all primers to 10 pmoles/µl. The recipe for 
PCR amplification consisted of 4 µl of DNA extract, 1 µl of primer mix, 10 µl of Hot-Start Taq mastermix (Denville 
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Scientific, United States) and 5 µl of water. PCR was carried out with an Eppendorf Mastercycler X50a (Eppendorf, 
Germany) under the following cycling conditions: 94°C for 3 min, (94°C for 30 s, 62°C for 1 min, 72°C for 45 s) 
35 cycles, 72°C for 2 min and hold at 4°C. Following the PCR run, the PCR products were digested with Thermo 
Scientific FastDigest Ddel (HPyF3I) restriction enzyme kit. Digested products were separated on a 3% agarose gel. 
Products that were wild-type, heterozygous, and mutant had the following band sizes: 155 bp; 155 bp, 100 bp and 
55 bp; and 55 bp respectively. 
 
4.3.3  PCR Screening for Mice Genotype – Eμ-myc 
 
Genomic DNA extractions from mouse tails were done with the same kit as above. The same concentrations for 
stock primers and primer mixes were also used. The following stock primers were utilized as recommended by 
JAX Laboratory: 14377 transgene forward, 5’-TTA GAC GTC AGG TGG CAC TT-3’; 14378 transgene reverse, 5’-
TGA GCA AAA ACA GGA AGG CA-3’; oIMR7338 internal positive control forward, 5’-CTA GGC CAC AGA ATT 
GAA AGA TCT-3’; and oIMR7339 internal positive control reverse 5’-GTA GGT GGA AAT TCT AGC ATC ATC C-
3’. The PCR recipe is as follows: 4 µl of DNA extract, 0.7 µl of primer mix, 10 µl of Hot-Start Taq mastermix and 
5.3 µl of water. PCR amplification was carried out with an Eppendorf Mastercycler X50a using the following cycling 
conditions: 94°C for 4 min, (94°C for 20 s, 65°C for 20 s, 68°C for 25 s) 10 cycles, (94°C for 20 s, 60°C for 20 
s, 72°C for 20 s) 28 cycles, 72°C for 2 min and hold at 4°C. PCR Products were separated on a 3% agarose gel 







4.3.4  Blood Collection 
 
All mice were anaesthetized with isoflurane (Zoetis Inc., Kalamazoo, MI) using the open-drop method prior to 
blood collection. Whole blood was collected from each mouse via jugular vein puncture with a 20G needle. Blood 
was collected and placed in a dipotassium ethylenediaminetetraacetic acid (K2EDTA) tube (BD Microtainer, Becton, 
Dickinson and Company, Franklin Lakes, NJ), followed by tube inversion several times to mix the blood. All 
samples were kept at 4°C prior to hematology analysis to be performed within 24 hours. 
 
4.3.5  Hematology 
 
A complete blood count (CBC) was performed using an automated hematology analyzer (Vet abc, Scil Animal 
Care, Gurnee, IL).  Additionally, a blood smear was prepared and stained (Aerospray 7120, Wescor, Logan, UT) 
using routine clinical laboratory methods, and reviewed by a board-certified veterinary clinical pathologist (MMF).  
 
4.3.6  Tissue Fixation and Evaluation 
 
At necropsy, the tissues were collected, fixed in 10% neutral buffered formalin. After 24 hours of fixation, the 
tissues underwent routine processing, paraffin-embedding, sectioning, hematoxylin and eosin staining, and 
microscopic evaluation by a board-certified veterinary pathologist (KN). 
 
4.4  Results and Discussion 
 
Mice were injected according to the schedule in Table 4.1 after confirmation of obesity and/or B-cell 
lymphoma status (Appendix C.1). Their corresponding weights can also be seen in Table 4.2. Samples for blood 
collection revealed that mice that were found to have the Eµ-myc transgene, as determined by PCR genotyping, 
also had increased white blood cell count when compared on average to the rest of the non-transgenic mice 
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(Table 4.3 and Figure 4.1). Cell volume and morphology from healthy and Eµ-myc transgenic mice also provided 
more evidence of hematologic malignancy. Micrographs of blood smear samples from non-transgenic and Eµ-
myc transgenic mice illustrated that mice with the transgene exhibited larger cells than those from non-transgenic 
mice, which is consistent with identification of malignant c-myc lymphocytes (Figure 4.2).22 Mice with the Eµ-myc 
transgene (PD5, C35, C6; Table 4.1, Figure 4.2) were categorized as having lymphoid leukemia or stage V 
lymphoma based on the hematology results. 
 These findings were also confirmed from a histological examination of spleen and lymph node tissue 
samples (Table 4.4, Figure 4.3 – 4.5). We can see from Figure 4.5 that the lymph node tumor of the ob/OB x Eµ-
myc male (C35) mouse did not have any remaining lymph node architecture; furthermore, cells were extending 
beyond the lymph node capsule. Cells going beyond the lymph node capsule would indicate that the disease 
could metastasize.23-24 In Figure 4.5C we also clearly see the presence of monomorphic populations of large 
lymphocytes and frequent mitosis occurring. Frequent clusters of apoptotic cells were also observed. All of this 
indicates a rapid proliferation and death of cells which are characteristic of cancerous cell populations.25-26  
Diagnosis of the spleen (C35) indicated marked follicular lymphoid hyperplasia (MFLH) and 
extramedullary hematopoiesis (MEMH). Follicular hyperplasia is a typical cause of lymph node enlargement mainly 
due to an increase in the number of B-cells that become larger and proliferate rapidly.27 However, follicular 
hyperplasia diagnosis can be benign as opposed to follicular lymphoma which is a common malignant NHL.28 
MEMH may indicate an infiltration of neoplastic cells,29 as seen by the large spleen (Table 4.5), and it could also 
signify a steady supply of monocytes to the tumor site.30 However, EMH on its own as an assessment of 
lymphoma pathologies by extramedullary hematopoiesis can be rather obscure and has often been relegated as an 
epiphenomenon.31 Therefore, a complete evaluation of other potential factors as we have determined, is necessary 
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for a clear diagnosis. Altogether, the data and diagnosis are in sync and undoubtedly identify B-cell lymphoma in 
ob/OB x Eµ-myc mice. 
 Comparing the ob/OB x Eµ-myc female (C36) mouse that displayed mild follicular lymphoid hyperplasia 
(MIFLH) with the male mouse (C35) that was diagnosed with MFLH in the spleen, we see that apart from gender 
differences, the other main factor that distinguishes the two are their diets. The female was fed a low-fat diet while 
the male was fed a high-fat diet, which may account for differences in their diagnosis. When the ob/OB x Eµ-myc 
female is compared to her ob/OB (C38) counterpart, their diagnosis for follicular lymphoid hyperplasia is similar 
but EMH for ob/OB (C38) was considered mild. The identification of MFLH in spleen was also determined for all 
mice fed a high-fat diet regardless of gender, weight or differences in obesity and Eµ-myc status. This agrees with 
other research studies that have shown an increase in splenic hyperplasia as a result of consuming high-fat 
diets.32-35  
 Lymphoid cholesterol granuloma in the lymph nodes of female ob/ob (C28 and C29) mice is indicative of 
their obesity status and intake of high-fat diets. These mice were placed on a high-fat diet for 8 weeks and had an 
average weight of about 60 g. The presence of foamy macrophages in the lymph node (Figure 4.4) is also a 
prominent feature of these cells that can result from consuming diets high in fat.36-37 In the lymph node of this 
female ob/ob (C28) mouse, even though there was MFLH, the lymph node architecture was retained as opposed 
to a distortion of lymph node architecture in the male ob/OB x Eµ-myc mouse (C35). Germinal centers in the 
lymph node of the female ob/ob (C28) mouse also displayed larger B-cells with smaller surrounding lymphocytes, 
but with rare mitotic and apoptotic cell events. The spleen of ob/ob female mouse (Figure 4.3) showed an 
expansion of periarteriolar lymphoid sheath from lymphocyte hyperplasia and the red pulp displayed EMH. This is 
interesting since this mouse (C28) was injected with PTX which is well-known to deplete lymphocyte numbers in 
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tissues and has been found by researchers to cause mouse splenic lymphocytes to be hyporesponsive.38-40 
However, there could be lymphocyte repopulation following paclitaxel therapy (i.e. after gaps in treatment) 
potentially due to B-cell diversity and/or a recovering immune system.41-42 Although the exact mechanisms are 
unclear, the combined treatments of high-fat diet and 5 mg/kg PTX induced lymphoid hyperplasia in ob/ob female 
mouse. The identification of EMH could also be as a result of PTX and/or a high-fat diet since EMH is a known 
occurrence following administration paclitaxel and other chemotherapeutic agents.43-44  
The combined results from our tests should aid in guiding future experiments. One of the major areas to 
explore would be an introduction of flow cytometry methods that can differentiate between B-cell subpopulations 
since the automated WBC count makes no distinction between normal and malignant populations. This would also 
help in resolving subpopulations that are like to be hyporeactive (or hyperactive) after treatment with any 
chemotherapeutic drugs. 
 
4.5  Conclusion 
 
 Overall, our findings demonstrate that there is the potential for obesity status and/or a diet high in fat to 
influence disease progression in B-cell malignancies. We propose that for a more definitive assessment of B-cell 
lymphoma pathologies, more tests would need to be incorporated to elucidate the mechanisms surrounding the 





Table 4.1  Experimental Outline of Injection Schedule, Blood Collection and Diet Placement 
 
Sample ID Gender Genotype 






PD1 – PD3 M ob/ob Tg- 
HFD, 15 wks post 
DOB / 3 wks 
-- 
3 wks post HFD 
placement 
PD4 F ob/ob Tg- 
HFD, 15 wks post 
DOB / 3 wks 
-- 
3 wks post HFD 
placement 
PD5* M ob/ob Tg+ 
HFD, 16 wks post 
DOB / 3 wks 
-- 
3 wks post HFD 
placement 
C1, C2 M OB/OB Tg- 
HFD, 12 wks post 
DOB / 9.5 wks 
Pbs/ 5 days 
pr.BC 
9.5 wks post HFD 
placement 
C3, C4* F OB/OB Tg- 
HFD, 12 wks, 14 
wks post DOB / 
9.5 wks 
Pbs/ 5 days 
pr.BC 
9.5 wks post HFD 
placement 
C5, C6 M OB/OB Tg- 
HFD, 12 wks post 
DOB / 10.5 wks 
Pbs/ 5 days 
pr.BC 
10.5 wks post 
HFD placement 
C7, C8* F OB/OB Tg- 
HFD, 12 wks, 14 
wks post DOB / 
10.5 wks 
Pbs/ 5 days 
pr.BC 
10.5 wks post 
HFD placement 
C9, C10 M OB/OB Tg- 
HFD, 12 wks post 
DOB / 11.5 wks 
Pbs/ 5 days 
pr.BC 
11.5 wks post 
HFD placement 
C11 F OB/OB Tg- 
HFD, 12 wks post 
DOB / 11.5 wks 
Pbs/ 5 days 
pr.BC 
11.5 wks post 
HFD placement 
C12, C13 M OB/OB Tg- 
HFD, 12 wks post 
DOB / 12.5 wks 
Pbs/ 6 days 
pr. BC 
12.5 wks post 
HFD placement 
C14 F OB/OB Tg- 
HFD, 12 wks post 
DOB / 12.5 wks 
Pbs/ 6 days 
pr. BC 
12.5 wks post 
HFD placement 
C16 F ob/ob Tg- 
HFD, 17 wks post 
DOB / 5 wks 
PTX/ 5 days 
pr.BC 
5 wks post HFD 
placement 
C17, C18 F ob/ob Tg- 
HFD, 16.5 wks 
post DOB / 5 wks 
PTX/ 5 days 
pr.BC 
5 wks post HFD 
placement 
C19* F ob/ob Tg- 
HFD, 12 wks post 
DOB / 5 wks 
PTX/ 5 days 
pr.BC 
5 wks post HFD 
placement 
C20 F ob/ob Tg- 
HFD, 17 wks post 
DOB / 5 wks 
PTX/ 5 days 
pr.BC 
5 wks post HFD 
placement 
C22 F ob/ob Tg- 
HFD, 17 wks post 
DOB / 7 wks 
PTX/ 5 days 
pr. BC 





Table 4.1  (continued) 
 
Sample ID Gender Genotype 






C23, C24 F ob/ob Tg- 
HFD, 16.5 wks 
post DOB / 7 wks 
PTX/ 5 days 
pr.BC 
7 wks post HFD 
placement 
C25* F ob/ob Tg- 
HFD, 12 wks post 
DOB / 7 wks 
PTX/ 5 days 
pr.BC 
7 wks post HFD 
placement 
C27 F ob/ob Tg- 
HFD, 17 wks post 
DOB / 8 wks 
PTX/ 5 days 
pr.BC 
8 wks post HFD 
placement 
C28, C29 F ob/ob Tg- 
HFD, 16.5 wks 
post DOB / 8 wks 
PTX/ 5 days 
pr.BC 
8 wks post HFD 
placement 
C30* F ob/ob Tg- 
HFD, 12 wks post 
DOB / 8 wks 
PTX/ 5 days 
pr.BC 
8 wks post HFD 
placement 
C35* M ob/OB Tg+ 
HFD, 14 wks post 
DOB/ 2 wks 
-- 
2 wks post HFD 
placement 
C36* F ob/OB Tg+ 
LFD, throughout 
lifespan 
-- 15 wks post DOB 
C37* M ob/OB Tg- 
HFD, 10 wks post 
DOB/ 2 wks 
-- 
2 wks post HFD 
placement 
C38* F ob/OB Tg- 
LFD, throughout 
lifespan 
-- 15 wks post DOB 
ob/ob, homozygous knockout for leptin; OB/OB, wild-type; ob/OB, heterozygous for leptin;  
Tg, B6.Cg-Tg(IghMyc)22Bri/J; Tg+, positive for transgene; Tg-, negative for transgene; pr.BC, prior to blood collection;  
HFD, high fat diet; LFD, low fat diet; DOB, date of birth 
*Differences in timing due to mice DOB 
** Mice that were placed on HFD were on LFD prior to diet change 
PD1 - PD5 (same BC group); C1 - C14 (same BC group); C16 - C30 (same BC group); C35 - C38 (same BC group). a1: PD1 (1 distinct M), a2: PD2 (1 distinct 
M), a3: PD3 (1 distinct M), a4: PD4 (1 distinct F), a5: PD5* (1 distinct M) [a1 to a4 born ~5 days after a5]; a6: C1, C5, C9, C12 (1 distinct M for 4 BCs), a7: C2, C6, 
C10, C13 (1 distinct M for 4 BCs), a8: C3, C7, C11, C14 (1 distinct F for 4 BCs), a9: C4, C8 (1 distinct F for 2 BCs) [a9 born ~3wks before other groups]; a10: 
C16, C22, C27 (1 distinct F for 3 BCs), a11: C17, C23, C28 (1 distinct F for 3 BCs), a12: C18, C24, C29 (1 distinct F for 3 BC), a13: C19, C25, C30 (1 distinct F for 
3 BCs), a14: C20 (1 F for BC) [a10 is the oldest. a11 & a12 are 6 days younger than a10. a14 is 5 wks younger than a10 and ~4.5 wks younger than a11 & a12]; 
a15: C35 (1 M for 1 BC), a16: C36 (1 F for 1 BC), a17: C37 (1 M for 1 BC), a18: C38 (1 F for 1 BC) [a15 is the oldest. a16 & a18 are 1 wk younger than a15. a17 





Table 4.2  Weight of Mice During Experiments* 
 
Sample ID Weight (g) Sample ID Weight (g) 
PD1, M 50.80 C16, F 58.82 
PD2, M 56.36 C17, F 54.93 
PD3, M 53.62 C18, F 54.60 
PD4, F 50.60 C19, F 54.25 
PD5, M 44.85 C20, F 60.30 
C1, M 38.54 C22, F 62.20 
C2, M 41.08 C23, F 59.70 
C3, F 24.45 C24, F 58.15 
C4, F 34.26 C25, F 58.94 
C5, M 37.89 C27, F 63.27 
C6, M 40.53 C28, F 61.78 
C7, F 24.15 C29, F 58.63 
C8, F 33.47 C30, F 60.49 
C9, M 37.86  C35, M 21.81 
C10, M 41.70 C36, F 18.53 
C11, F 24.48  C37, M 28.68 
C12, M 38.40 C38, F 20.86 
C13, M 41.80 -- -- 
C14, F 24.50 -- -- 




























Table 4.3  White Blood Cell Count from Blood of Eµ-myc Transgenic and Normal Mice  
 
  WBC (x103/µL) 
Sample ID Run 1 Run  2 Run 3 Mean Median 
PD1, M 8.8 8.7 8.0 8.5 8.7 
PD2, M 2.3 5.0 5.0 4.1 5.0 
PD3, M 6.2 6.2 6.5 6.3 6.2 
PD4, F 5.1 5.2 5.2 5.2 5.2 
PD5, M 20.5 20.0 19.7 20.1 20.0 
C1, M 3.1 6.1 3.1 4.1 3.1 
C2, M 7.1 7.2 7.1 7.1 7.1 
C3, F 4.2 4.2 3.8 4.1 4.2 
C4, F 4.2 4.2 4.2 4.2 4.2 
C5, M 8.3 8.2 7.8 8.1 8.2 
C6, M 8.2 9.0 9.2 8.8 9.0 
C7, F 5.1 4.7 4.9 4.9 4.9 
C8, F 5.6 5.4 5.8 5.6 5.6 
C9, M 4.8 4.7 4.7 4.7 4.7 
C10, M 4.7 4.4 4.0 4.4 4.4 
C11, F 3.2 3.0 3.3 3.2 3.2 
C12, M 6.1 5.5 5.6 5.7 5.6 
C13, M 6.1 6.2 6.3 6.2 6.2 
C14, F 3.9 4.1 3.8 3.9 3.9 
C22, F 11.5 11.6 11.8 11.6 11.6 
C23, F 6.4 5.5 6.2 6.0 6.2 
C24, F 12.8 12.4 12.1 12.4 12.4 
C25, F 14.7 13.7 14.7 14.4 14.7 
C27, F 7.4 7.2 7.1 7.2 7.2 
C28, F 2.1 2.3 2.2 2.2 2.2 
C29, F 12.2 11.2 12.0 11.8 12.0 
C30, F 10.2 10.2 10.5 10.3 10.2 
 C35, M 32.6 38.1 37.1 35.9 37.1 
C36, F 18.6 18.5 18.1 18.4 18.5 
 C37, M 3.9 3.7 3.8 3.8 3.8 











Figure 4.2  Blood smear showing morphology of granulocytes and lymphoblasts (60x). (A) C13 – showing no 
evidence of malignancy. (B) C35 – showing three large cells consistent with malignant lymphocytes; one small 
lymphocyte, likely benign; one neutrophil; one lysed cell. (C) C36 – Two large cells consistent with malignant 
lymphocytes; one small lymphocyte, likely benign; one neutrophil. (D) PD5 – Three large cells consistent with 










Table 4.4  Histological Classification for Spleen and Lymph Node Tissues of Normal and Eµ-myc Mice 
 
Sample ID Tissue Diagnosis 
C12, M Spleen 
Marked follicular lymphoid 
hyperplasia 
C13, M Spleen 
Marked follicular lymphoid 
hyperplasia 
C14, F Spleen 
Marked follicular lymphoid 
hyperplasia 
C27, F Spleen 
Marked follicular lymphoid 
hyperplasia & EMH 
C28, F Spleen 
Marked follicular lymphoid 
hyperplasia & EMH 
C28, F Lymph node 
Lymphoid hyperplasia cholesterol 
granuloma 
C29, F Spleen 
Marked follicular lymphoid 
hyperplasia & EMH 
C29, F Lymph node (by pancreas) 
Lymphoid hyperplasia cholesterol 
granuloma 
C29, F Lymph node (by salivary gland) Lots of mast cells 
C30, F Spleen 
Marked follicular lymphoid 
hyperplasia & EMH 
C35, M Spleen 
Marked follicular lymphoid 
hyperplasia & EMH 
C35, M Lymph node (by pancreas) 
Lots of histiocytes in peripancreatic 
lymph node 
C35, M Lymph node (by salivary gland) Lymphosarcoma 
C36, F Spleen 
Mild lymphoid hyperplasia & 
moderate EMH 
C36, F Skin with skeletal muscle Lymphosarcoma 
C37, M Spleen 
Marked follicular lymphoid 
hyperplasia 
C38, F Spleen Mild lymphoid hyperplasia & EMH 












Figure 4.3  Spleen Histology of ob/ob Female (C28) Mice on a High Fat Diet for 8 weeks and following 3 
Consecutive Week Injections of 5mg/kg PTX. (A) and (B) show the expansion of periarteriolar lymphoid sheaths, 
100x and 200x respectively. (C) Extramedullary hematopoiesis in the red pulp (400x). (D) Enlarged view of the 















Figure 4.4  Histology of Lymph Node of ob/ob Female Mice (C28) on a High Fat Diet for 8 weeks and following 3 
Consecutive Week Injections of 5mg/kg PTX. (A), (B) and (C) show the central germinal centers with larger cells 
surrounded by small lymphocytes. (D) Enlarged imaged from image [E] showing the cholesterol cleft and the 
formation of a multinucleated giant cell (400x). (E) Lymph node expanded by cholesterol granuloma (100x). (F) 






Figure 4.5  Histology of Lymph Nodes of Male (C35) ob/OB x Eµ-myc Mouse on a High Fat Diet for 2 weeks. (A) 
Showing no lymph node architecture and cells extending beyond the capsule (200x). (B) Enlarged image showing 
lymph node capsule (400x). (C) Monomorphic populations of large round cells with frequent mitoses (orange 










Table 4.5  Weights of Spleen and Lymph Node in C35-C38 
 
Sample ID Spleen Weight (mg) Lymph Node (mg) 
C35, M 249.7 664.8*, 504.7*,1051.2** 
C36, F 322.2 671.0 
C37, M 64.5 4.5 
C38, F 60.6 5.0 
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Figure C.1  Representative PCR results from the tail biopsies displaying the Lepob and Eμ-myc status of bred 
mice. 324 bp, internal positive control. 210 bp, B-cell lymphoma status. 155 bp; 155 bp, 100 bp and 55 bp; and 


















































5.1  Conclusion 
 
 Lipoproteins can direct intravenously injected nanoparticles away from their target sites and onto 
lipoproteins receptors in the body. Lipoproteins engage in lipid metabolism and thus the metabolic state of an 
individual as we have shown here can affect the biodistribution of injected nanoparticles. There are also gender-
related differences in terms of lipid metabolism, and these results as a whole should compel us to redefine our 
focus and how we conduct research in the field of nanomedicine. 
 Since the blood profile of each individual is unique and this is also affected by certain diseased states, we 
ought to narrow our focus of nanotherapy based on disease type, while also conditioning our treatments to the 
metabolic status of each individual. Obesity for example is one of such conditions where treatment for other 
diseases such as cancer on the same individual can be problematic since dosages and other underlying factors 
relating to adequacy of treatment and toxicity becomes an issue. It is therefore imperative that we expand our 
knowledge in this area since we showed here that the obesity status does affect biodistribution of nanoparticles.  
 In summary, our investigations communicate the need for taking into consideration the metabolic status 
of an individual when administering nanotherapeutic drugs since it can influence nanoparticle localization and also 
potentially worsen diseases such as cancer. 
 
5.2  Recommendations for Future Studies 
 
To further examine the effect of metabolic state in nanoparticle drug delivery, it is recommended that: 
(1) Future experiments be conducted that establish the molecular mechanisms behind the reduced 
localization of filomicelles to the organs of the liver and spleen in obese mice; possibly in relation to 
macrophage uptake and signaling events. 
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(2) In terms of lipoprotein and lipid metabolism, mice that have SCARBI-/- and LDLR-/- can potentially be 
used to identify further differences in plasma cholesterol uptake between the mouse genders. Additional 
studies using different diets (low-fat and high-fat diets) could possibly be utilized to determine how 
nanoparticle distribution is affected with mice embodying cholesterol plaques. 
(3) For the B-cell lymphoma research, a method (e.g. flow cytometry) of identifying different B-cell 
subpopulations in the blood and streamlining according to disease progression would be beneficial in 
comparing mice with different stages of the disease. Immunostaining of spleen and lymph node tissues 
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